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There is a growing need (in the medical field) to design personalized therapy for cancer 
patients. Decades of cancer research have found no silver bullet that can cure all or even most 
patients. This study evaluated four patients affected by central nervous system (CNS) tumors 
(Ependymoma and Glioblastoma), and found that tumors with the same histology had unique 
responses to treatment. Each sample presented different levels of heterogeneity in expressed 
biomarkers and responded to drugs at varying levels. 
Oncologists conventionally treat cancer patients with drugs tested in large clinical trials. 
However, often patients do not experience positive outcomes following treatments with standard-
of-care first line drugs and oncologists need to treat them with a different second-line anticancer 
therapy that is chosen empirically. This study was designed to find a way to better predict 
patient’s response to chemotherapeutic drugs. The focus of this study was on Central Nervous 
System (CNS) tumors because of their limited response to anticancer drugs and their low 
survival rate. The uniqueness of this study revealed that each patient’s tumor had different drug 
sensitivities and that screening for multiple drugs may increase the chance of finding a drug from 
which the patient would have the most benefit. 
 More importantly this study evaluated the Cancer Stem-Like Cell (CSLC) population 
sensitivity to these drugs. This subpopulation is responsible for initiation and maintenance of the 
tumor and is known to be resistant to chemotherapy drugs. Dr. Claudio’s laboratory developed a 
test capable of determining the cytotoxic drug to which cancer cells and CSLCs of an individual 
tumor are most responsive. In the future this procedure may focus the treatment of CNS patients 
to drugs effective against their particular tumor allowing them to have better outcomes with 
fewer detrimental side effects. 
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 The typical treatment for most cancer is surgery followed by chemotherapy and/or 
radiation therapy combined in various modalities (1). Ordinarily, the type of chemotherapy or 
amount used is based on histology, clinical characteristics of the patient, and retrospective 
evidence from randomized clinical trials (2). The standard approach for the treatment of brain 
cancer is also surgery followed by chemoradiation therapy. However; the chemotherapy choices 
are more limited due to the Blood Brain Barrier (BBB), which may limit diffusion of the drugs 
from the blood stream to the nervous tissue (3,4). There are several CNS tumor types and overall 
for all types of malignant brain tumors in adults, around four out of ten people diagnosed (40%) 
live for at least a year. About 19 out of every 100 people (19%) live for at least five years after 
diagnosis, and around 14 out of every 100 people diagnosed (14%) live for at least ten years. 
Unfortunately 50% of all CNS cancers diagnosed are Glioblastoma Multiforme (GBM), which 
shows the lowest survival rate of all, with survival only being 12-18 month after diagnosis (3). 
With such a short survival time, the patient rarely has a second or third round of treatment.  
 Oncologists cannot predict if a chemotherapeutic agent will be effective for a patient 
beforehand, all they can determine is that a particular drug has been effective in a percentage of 
patients either from their own experience or from large randomized clinical studies (2). Patients 
with the same tumor histotype often respond differently to the same chemotherapy regimen due 
to heterogeneity of the tumor (2). Following an initial treatment with drugs used as first-line 
chemotherapies, the treating physician will be able to determine if the patient is responding or 
not to a particular chemotherapy regimen. Tumor relapse may still occur in spite of an initial 
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response because of the presence of a subset of cells that are resistant to the treatment (5). Toxic 
side effects may also decrease patients’ quality of life. Most chemotherapies impact several 
important functions and organs of the human body that have cells undergoing a rapid turnover by 
having active cellular divisions, such as the hematopoietic compartment, the colon, and the hair 
follicles thereby causing immune depression, diarrhea, and hair loss.  Additionally, 
chemotherapy may also diminish the patients’ memory and learning abilities (6).  Therefore, it 
would be advantageous to both the patient and the doctor to know whether a chemotherapeutic 
agent will be effective against the patient’s tumor cells. This approach would increase efficacy 
against the tumor, reduce toxicity and side effects for the patient, prolong response, and reduce 
medical cost. 
 Because of these concerns many different scientists have been looking into therapeutic or 
diagnostic approaches to personalize patient therapy. Next Generation Sequencing (NGS) aims at 
determining genomic markers that would predict the patient’s sensitivity to a specific 
chemotherapeutic agent (7). Evidence linking genetic information to therapeutic effectiveness of 
treatments can be misleading. Following the discovered association of KRAS mutations with 
resistance to anti‐EGFR antibodies, some studies have shown that tumors with normal ‘wild‐
type’ KRAS profile, still do not respond to therapy (8). This type of research is still in its infancy 
and needs more time to progress as research furthers the understanding of tumor biology. 
Other researchers have developed a method to determine the sensitivity of cancer cells to 
chemotherapeutic agents (total cancer cell population). However, their studies show no accurate 
and statistically significant correlation to patients’ disease outcomes (9-12). In the present study 
the developed method for personalized chemotherapy uses a biopsy from the patient, which 
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 There are several types of tumors of the central nervous system (CNS); however CNS 
tumors are only 1.4% of all new cancers diagnosed in the United States (13) (SEER Stat Fact 
Sheets: Brain and Other Nervous System Cancer. 
http://seer.cancer.gov/statfacts/html/brain.html). Gliomas are typically found in adult cases and 
are fast growing brain tumors typically arising from the supportive tissue of the brain: the “glia”.  
Three types of normal cells that constitute the glia can become cancerous. Astrocytes will form 
astrocytomas, including glioblastoma. Oligodendrocytes will transform into oligodendrogliomas, 
and ependymal cells form ependymomas (13,14). Gliomas are further classified by the World 
Health Organization (WHO) according to their grade. Low grade gliomas (WHO grade II) are 
well differentiated tumors that tend to have better prognoses. High-grade gliomas (WHO grade 
III Astrocytoma, WHO grade III Ependymoma, and WHO grade IV glioblastomas) are 
undifferentiated (anaplastic) and carry the worse prognosis. The highly malignant anaplastic 
gliomas display hypercellularity, nuclear atypia, and high mitotic activities at histopathologic 
examination (13,14). This study focused on high-grade Astrocytomas known as Glioblastoma 








Several factors were taken into account when determining what drugs would be used for 
this study. 1. NCCN guide lines, 2. Treating Physician and Pharmacist consultation, 3. 
Availability of drug. 4. Mechanism of drugs cytotoxicity. All mechanisms of action for drugs 
used were reviewed to ensure cytotoxicity was a measurable endpoint. 
Arabinoside-C (Ara-C), also known as Cytosine Arabinoside, interferes with the 
synthesis of DNA by rapidly conversion to Cytosine Arabinoside triphosphate, which damages 
DNA during DNA synthesis, and also inhibits both DNA and RNA polymerases and nucleotide 
reductase enzymes needed for DNA synthesis (15). 
 Bevacizumab (Avastin) is a monoclonal antibody, its mechanism of action is to block 
angiogenesis by inhibiting vascular endothelial growth factor A (VEGF-A) (16). The antibody 
stops the receptor from being activated and cuts off any new blood supply to the growing tumor, 
causing the growth to stop (17). However, this drug has been known to also have cytotoxic 
effects but the mechanism is still debated (18). VEGF-targeted therapies, such as bevacizumab, 
exert their effects through a number of potential mechanisms, including (1) inhibition of new 
vessel growth, (2) regression of newly formed tumor vasculature, (3) alteration of vascular 
function and tumor blood flow ("normalization"), and (4) direct effects on tumor cells by 
activation of apoptosis (19). 
Busulfan (BUS) is an alkylating agent that forms DNA-DNA crosslinks between the 
DNA bases guanine and adenine and between guanine and guanine which prevents DNA 
replication (20). These DNA crosslinks cannot be repaired, so the cells undergo apoptosis. 
Carboplatin (CPL) is a second generation platinum drug (21). Two mechanisms of action 
have been proposed: the aquation hypothesis and the activation hypothesis (22). The aquation 
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hypothesis proposes that the drug complex aquates and reacts with DNA like cisplatin (22,23). 
The difference is in the rate of activity between the faster Carboplatin and Cisplatin (24). The 
activation hypothesis assumes that Carboplatin is biologically activated and that it is an unknown 
platinum species that binds to the DNA (22). Carboplatin requires a much lower and more 
tolerable dose that is then activated within the cell itself (22). 
Carmustine (BCNU) is a mustard gas compound used as an alkylating agent in 
chemotherapy (25). It disassociates to yield 2-chloroethyl isocyanate and the chloroethyl 
carbonium ion intermediate, which is the alkylating moiety (25). As an alkylating agent, BCNU 
is able to form interstrand crosslinks in DNA; thereby DNA cannot replicate or be transcribed 
(25).  
Cisplatin (CDDP) is a platinum drug that causes DNA intrastrand cross-links between 
two adjacent guanine residues on the same DNA strand (6,21,23). Patients that have 
overexpression of ABCG2 and other multidrug resistance are not responsive to CDDP (6). It is 
of note that CDDP causes severe toxicity, which has led to the development of several second 
generation platinum drugs (21,26). 
Topoisomerase II is a primary cellular target for Etoposide (VP-16) (27). Without 
topoisomerase II cells cannot resolve the knots and tangles in the genetic material that are 
produced by normal cellular processes (27). Etoposide inhibits topoisomerase II and in its 
absence the cells are unable to replicate DNA and the cells die as a consequence of mitotic 
failure (27). 
Irinotecan (Camptosar, CPT-11) is a topoisomerase-I inhibitor, which is a nuclear 
enzyme associated with relaxation of the supercoiled DNA (28,29) that produces reversible 
single-strand breaks in DNA during DNA replication. These single-strand breaks relieve 
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torsional strain and allow DNA replication to proceed. Irinotecan binds to the topoisomerase I-
DNA complex and prevents religation of the DNA strand, resulting in double-strand DNA 
breakage and cell death (29).  
Lomustine (CCNU) is another DNA alkylating agent (30,31). Lomustine’s full 
mechanism of action has not been fully understood but more recent studies have shown that 
CCNU triggers apoptosis through the intrinsic apoptosis mitochondrial pathway (31). Its 
mechanism of action also involves the inhibition of both DNA and RNA synthesis through DNA 
alkylation. Lomustine has been shown to affect a number of cellular processes including: RNA 
and protein synthesis; the processing of ribosomal and nucleoplasmic messenger RNA; DNA 
base component structure; the rate of DNA synthesis and DNA polymerase activity. It is cell 
cycle nonspecific. 
Methotrexate (MTX) binds to and competitively inhibits Dihydrofolate Reductase 
(DHFR) an enzyme that participates in tetrahydrofolate synthesis (32). Without this reaction the 
biosynthesis of purines, thymidylate, and several amino acids is inhibited and the cells cannot 
replicate or repair DNA (32). 
Oxaliplatin (OXA), like the other platinum drugs causes intrastrand adducts. Oxaliplatin 
belongs to the 1,2-diaminocyclohexane (DACH) carrier ligand family whereas cisplatin and 
carboplatin belong to cis-diammine. Oxaliplatin is a bulky hydrophobic DACH ligand, which 
prevents binding of DNA repair proteins (23). This was the first drug approved that could 
overcome cisplatin resistance (23,26).  
Procarbazine (PCB) has multiple mechanisms of action (33). It inhibits incorporation of 
small DNA precursors, as well as inhibits RNA and protein synthesis (33). PCB can also directly 
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damage DNA through an alkylation and methylation reaction (33,34). It is almost always 
administered in combination with CCNU and VCR (33,35). 
Temodar (TMZ) is commonly used as a first-line drug for high grade gliomas (6). TMZ is 
a DNA-alkylating agent and methylating agent (6,35) which delivers a methyl group to purine 
bases of DNA (O6-guanine; N7-guanine and N3-adenine). This methylation of guanine residues 
leads to single and double-strand DNA breaks and subsequent apoptotic cell death. 
Vincristine (VCR) is an alkaloid derived from Vinca rosea Linn (36). It is known to 
disrupt mitosis by interfering with microtubules. Like other vinca alkaloids, Vincristine may also 
interfere with: 1) amino acid, cyclic AMP, and glutathione metabolism, 2) calmodulin-dependent 
Ca2+-transport ATPase activity, 3) cellular respiration, and 4) nucleic acid and lipid biosynthesis 
(30,37).  
 
Cancer Stem Cell Theory 
 Dr. John Dick is credited with the discovery of Cancer Stem-Like Cells. The Cancer 
Stem-Like Cell theory describes cancer stem-like cells (CSLCs) as a subpopulation that initiates 
and maintains cancer, allowing for recurrence and therapy resistance (38-40). However, since 
then the Cancer Stem-Like Cell theory has been one of controversy (41). “This controversy 
developed because “the definition” of a cancer stem cell needs to be linked to the functional 
assay that is used to identify it. Also it needs to be clearly understood that the “cell of origin” 
(stem cell or not) represents a different issue” according to Dr. John Dick (42).   
The consistent question is whether a cancer always originates from normal stem cells 
which lose the control of proliferation and differentiation, or is it a differentiated cell that 
becomes more stem-like after acquiring mutations (42-44). Defining CSLCs as a subpopulation 
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of tumor cells able to develop their cancer tissue type and regenerate a phenotypically 
heterogeneous cell line, like that of the original tumor, implies that CSLCs are the driving force 
of cancer recurrence (5). The difficulty to experimentally address this question arises from the 
limited quantity of this subpopulation of CSLCs in a given tumor (43). This may one day be 
addressed by the ability to isolate and enrich this population (45). 
This study evaluates CD133+ subpopulation of CNS tumors for isolation and testing.  
CD133 is also known as Prominin-1 (Prom-1), a pentaspan membrane glycoprotein (46). CD133 
was first identified as a hematopoietic stem cell marker and since then has been shown to be a 
marker of cancer stem-like cells with prominent tumorigenic potential (46). Its function is not 
fully understood but is believed that in tumor cells it regulates the proliferation and colony-
formation of cancer cells (6, 45-50). CD133 has also been associated with CSLC population in 
many tumor types including Glioblastoma, Ependymoma, Medulloblastoma, and Meningioma 
(47-49). The role of CD133 as a CSLC marker has been actively investigated over the years (46). 
It is accepted that glioma stem-like cells have high expression of CD133 that is similar to neural 
stem/progenitor cells (6,46).  
 
Clinical Study 
 The clinical study using the chemosensitivity assay was set up with the following steps:  
1. Receive the biopsy. 2. Disassociate and grow the cells in a monolayer. 3. Determine the 
biomarkers that identify CSLCs. 4. Treat bulk cells with various chemotherapeutic agents. 5. 
Expand CSLCs and treat them with various chemotherapeutic agents. 6. Analysis of 
chemosensitivity data and correlation to clinical outcome. 
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 The tumor biopsies from the CNS patients were received in a transfer/collection media 
tube. This consisted of RPMI and 10% FBS with 4% Penicillin/Streptomycin. During surgery a 
piece of the tumor was collected and placed in this collection tube, which allowed time for any 
introduced contamination to be exposed to high levels of antibiotic, reducing the risk of growth 
of contaminant bacteria. Culture viability tests were run to show that the tissue remained viable 






Figure 1. CNS Tumor collected and processed at different times after collection.  
Once biopsy was received tissue was cut into three pieces. Top: Tissue was processed immediately and 
incubated for five days. Middle: Tissue was left in test tube with transfer/collection media for three days 
at room temperature then processed and incubated for five days. Bottom: Tissue was left in test tube with 
transfer/collection media for five days at room temperature then processed and incubated for five days. 
  
Once received by the lab the tissue was washed thoroughly. If the received tissue was 
bloody, then it was washed with PBS several times in attempt to reduce the amount of Red Blood 
Cells (RBCs) that would be in the culture. After this initial washing, one more wash with 100% 
Penicillin/Streptomycin was conducted before manual disassociation technique. To manually 
disassociate the tissue a sterile scalpel was used to mince the tissue. The minced tissue was 
collected into a 15 mL sterile tube with equal amounts of 0.25% Trypsin and 0.1uM EDTA 
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Accutase. The volume of trypsin and accutase mixture varied based on the amount of tissue 
received. The tube was then placed in a 37°C water bath for 5-15 minutes (until the solution 
looked cloudy) and then the tissue was transferred into a tissue culture treated dish and normal 
culture media was added to stop the digestion (45,50). The primary culture was observed using a 
bright field inverted microscope every day for about two weeks and then a regular sub culture 
technique began (45,50). Once several tissue culture treated dishes were sub-cultured, several 
stocks were made and cryopreserved. 
 To determine presence of CSLCs in the primary culture obtained, flow cytometry using 
fluorescent antibodies against known CSLC markers were used (3,6,38,40,45-55). For flow 
cytometry analysis, 1x10 primary cells were collected, stained using specific antibodies and 
analyzed using an Accuri C6 Flow Cytometer (45,50). Unspecific isotype antibodies were used 
as controls. The isotype control is a base antibody with just the unspecific clone that has a 
fluorescent marker added; it detects unspecific binding to remove any false positives from the 
test. Expression of every marker tested was calculated by subtracting the value calculated from 
sample stained with the isotype antibody. This initial testing is important to verify that the 
CSLCs are enriched in the following steps of the test. 
 The amounts of drugs were based on the clinical dose. The equations used were: Stock 
concentration	() = (		/.. ) ∗ 1000, In vitro dose() =
(		(/) ∗ 1.6)/.. , Amount of stock needed to treat cells 
= (	 	/!	) ∗ 1000 = ul of stock/ml of media. This concentration 
was added to the culturing medium to treat the cells for a one hour pulse to mimic the highest 
concentration of chemotherapy drug to which cancer cells would be exposed in a treated patient. 
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Medium was then removed and cells were fed with complete medium containing 10% FBS for 
24 hours and assayed using an MTT assay.   
 Methyl-Thiazolyl-Tetrazolium (MTT) proved to be an accurate assay for determining cell 
viability for this chemotherapy sensitivity assay (56).  MTT is a yellow powder called (3-(4, 5-
dimethylthiazole-2-yl)-2, 5-diphenyltetrazoli-umbromide) that is reduced by mitochondrial 
dehydrogenase in viable cells, forming a purple formazan precipitant (56). After a 2-4 hour 
incubation the media with MTT is removed and the precipitant can then be solubilized using 
50ul of DMSO per well. Once the 96 well plate is briefly shaken the plate can be read on a 
spectrophotometer at 550nm absorbance. The readings provide the absorbance of the control and 
each of the treatments, by taking the (mean of the treatments/means of the controls)*100= % 
viable compared to control. This assay is widely used to assess cell viability after imitation of 
cytotoxicity (57), however this has been challenged in recent years. One reason that this is 
challenged is because MTT can react with compounds used in treatment. This was avoided by 
mixing the chemotherapeutic agents used with the MTT and evaluating the absorbance. No 
change was found (data not shown). The other challenge with using the MTT assay is that not all 
cells have the same amount of mitochondrial activity which is where the MTT is enzymatically 
changed into the purple formazan percipient. This is especially a problem with established cell 
cultured lines. It was found in primary lines to be less of a challenge because less genetic shifts 
have happened. However, a comparison of the MTT assay to several other types of viability 
assays (CyQUANT, WST-8, and ATP luciferase) was performed on the primary cultures and 
found that there was no statistical difference among the different types of assays tested (Figure 
2). In particular, the WST-8 assay was found to be a more reliable alternative if cells were not 
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attaching to the surface of the 96-well dishes because WST-8 is water soluble and it doesn’t 




Figure 2. MTT vs. CyQUANT vs. WST-8 vs. ATP. 
Using a GBM primary cell line to compare MTT assay, CyQUANT, WST-8 and ATP luciferase assay. 
Each assay was plated with 1x104 cells per well.  All assays were treated with one-hour pulse of 





Isolation of CSLCs from the tumors was accomplished by either magnetic bead sorting of 
the CD133+ population or by using the Hydrodynamic Focusing Bioreactor (HFB). To 
determine if these methods produced the same results, different isolation methods were 
compared and found that the response to the drugs was not statistically significant (Figure 3).  
However, it was also determined that in order to obtain the necessary number of sub-confluent 
plates of cells to be used in a magnetic bead sort of CD133+ cells useful to perform a 
chemosensitivity assay it would take around two months of tissue culture vs. the seven days 
process when using the HFB (45).    
 
 
Figure 3. Drug Response to: HFB vs. MACSorted CD133 Isolation. 
Same GBM cell line was used to compare the CD133 population of cells isolated by HFB vs. MACSorted 
CD133 Microbeads kit. Each assay was plated with 1x104 cells per well.  All assays were treated with one 
hour pulse of chemotherapeutic agents then analyzed 24 hours later with MTT.  P-value was greater than 




After bulk of tumor cells and CSLCs of each primary patient cell line were tested to 
determine the response to the various drugs by MTT assay, the samples were analyzed by 
calculating the percentage of cellular viability against the control using the following formula: 
(" 			/	#	" ) 	∗ 100	 =
	%	%&	#	'		# 
Percent of non-viable cells were calculated using the following formula:	100 −
%	%&	# = %	#	).  Drug response was reported by assigning samples in which it 
was found that there was between 60-100% Cell Kill to a responsive category; followed by 30-
59.9% Cell Kill to be intermediate responsive; and 29.9-0% to be non-responsive.  
Standard deviation was calculated off of the mean absorbance of the MTT assay for each 
treatment and multiplied by 100 to get the percent standard deviation. If this number was greater 
then 5% one value would be removed using the student t-test. If less than 5% standard deviation 
was still not achieved then whole test would be run again. 
Disease outcomes were correlated to the determination of chemosensitivity to the specific 
chemotherapy drug that was administered to the patient to determine clinical correlation with the 
in vitro chemosensitivity assay.  
 
Chemotherapy Sensitivity Assay Validation 
This assay has been recently validated in compliance with CLIA regulations 
(42CFR493.1291 (3)). Accuracy and precision were assayed by a minimum of three (3) repeats 
of the chemotherapy sensitivity assay, with three (3) established cell lines with unique 
chemotherapeutic response profiles covering the spectrum of the detectable range of <10% to 
100% cell viability. 
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Quantitative agreement, with less than 30% standard deviation, of cell viability for cell 
line HEK293, less than 16% standard deviation for cell line SW480, and less than 18% standard 
deviation cell viability for cell line DU145 were the intended goals. These standard deviations 
were determined by assaying growth control plates for the established cell lines which were used 
to ascertain their base mitochondrial activity in relation to cell viability. 
Growth control plates were established by plating 10,000 cells/ml of each cell line in a 
series of wells. These plates followed the same incubation periods and were treated the same as a 
regular assay as outlined in the chemotherapy sensitivity assay, except they were not treated with 
any chemotherapeutics. Absorbance readings were taken and from those, percent cell viability 
was calculated. The difference in the range of cell viability determined the acceptable percent 
standard deviation for that cell line.  
Repeatability was measured by the performance of two runs of the assay for each 
chemotherapeutic (dosage and infusion rate) by the same person. Agreement between these two 
runs is expected to be less than the acceptable standard deviation for that cell line determined by 
the growth control plate. 
Reproducibility was measured by the performance of the test being analyzed on 
discontinuous days by a different person and contributed to the overall accuracy of the test.  
Within-run repeatability was assessed by the four (4) repeats per chemotherapeutic per 
assay that are standard to the chemotherapy sensitivity assay. The standard deviation of these 
four repeats shall be no greater than 5%. One outlier per the four repeats per chemotherapeutic 
can be thrown out per standard operating procedure for the chemotherapy sensitivity assay and 
still achieve statistical significance. 
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Repeatability: 99.5% of all repeats matched within the acceptable standard deviation. 
Reproducibility: 95.5% of all repeats matched within the acceptable standard deviation. Within-
Run Repeatability: 99.7% of all repeats per chemotherapeutic per run matched within a 5% 
standard deviation.  
Analytical sensitivity was tested by treating 10,000 cells/ml with 100µl of 100% ethanol. 
Ethanol, used as a positive control in the chemotherapy sensitivity assay, will kill the majority of 
the living cells. The resultant absorbance readings showed that cell viability ranged from 1.2% to 
11.2% across varying cell lines showing that chemotherapy sensitivity assay can detect living 
cells in the range of 120 – 1,120 cells/ml. Thus a range of <10% cell viability is the minimum 
limit of the chemotherapy sensitivity assay's sensitivity to be reported on diagnostic tests. 
Analytical specificity was tested by attempting chemotherapy sensitivity assay on non-
neoplastic cells. The percentage of normal stem cells that grew or survived during the initial 
growth period prior to chemotherapy analysis was too low to perform the chemotherapy 
sensitivity assay showing that only neoplastic cells can survive the culture growth period in 
testable numbers.  
Robustness of this lab developed test was assessed by observing the culture growth of 
CNS tumor tissue samples stored in varying media and conditions. This condition was successful 
in producing enough cells for analysis: RPMI-1640 + 10% FBS + 2% P/S stored at room 
temperature. These conditions were deemed unsuccessful for chemotherapy sensitivity assay 
analysis: RPMI-1640 + 10% FBS + 2% P/S stored at 4ºC for up to 2 hrs, Saline stored at room 




Figure 4. Robustness Testing on Primary Tumor Tissue. 
A) Media: RPMI + 10% FBS + 2% P/S Storage condition: Room temp. Growth period: expected growth 
after 7-day incubation. B) Media:  RPMI + 10% FBS + 2% P/S Storage condition:  4ºC for 2 hrs. Growth 
period:  no growth after 7-day incubation. C) Media:  Saline Storage condition:  Room temp for 2 hrs. 
Growth period: slow growth after 7-day incubation. D) Media:  Ethanol Storage condition:  Room 
temp for 2 hrs. Growth period: slow to no growth after 7-day incubation. 
 
 
Reportable range was confirmed by testing cell lines ranging from <10% viability to 
100% viability and unique chemotherapeutic response profiles were generated for each cell line. 





The drug response assay tested for both the sensitivity to standard-of-care drugs on the 
overall tumor (Bulk) and the CSLC population. By challenging these cells with the different 
chemotherapeutic agents the test was able to determine ineffective drugs that could be excluded 
from the panel of drugs used by the treating physician.  
This study investigated 4 cases of CNS malignant tumors, two Ependymoma and two 
Glioblastoma. When these cases were treated with standard-of-care chemotherapy drugs the 
tumors should have responded in a similar fashion, however, the data accrued in this study shows 
that patients had better outcomes when treated with effective chemotherapies against CSLC. It is 
important to note that response of CSLCs to the treating chemotherapies indicated the patient 
disease outcome in both cases. While many other CNS cases have been studied with this method, 




CHAPTER 2: CASE STUDY OF EPENDYMOMA 
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Administration of ineffective anticancer therapy is associated with unnecessary toxicity 
and development of resistant clones. Cancer stem-like cells (CSLCs) resist chemotherapy, 
thereby causing relapse of the disease. Thus, development of a test that identifies the most 
effective chemotherapy management offers great promise for individualized anticancer 
treatments. This study was designed to investigate an ex vivo chemotherapy sensitivity assay, 
which measures the sensitivity of CSLCs as well as the bulk of tumor cells to a variety of 
chemotherapy agents. Two patients, a 21-year old male (patient 1) and a 5-month female (patient 
2), affected by anaplastic WHO grade-III Ependymoma were screened using the chemotherapy 
sensitivity assay. Patient 1 was found sensitive to the combination of Irinotecan and 
Bevacizumab, which resulted in a prolonged disease progression free period of 18 months. 
Following recurrence, the combination of various chemotherapy drugs was tested again with the 
chemotherapy sensitivity assay. This study found that benzyl isothiocyanate (BITC) greatly 
increased the chemosensitivity of the Ependymoma cells to the combination of Irinotecan and 
Bevacizumab. After patient 1 was treated for two months with Irinotecan, Bevacizumab and 
supplements of cruciferous vegetable extracts containing BITC, 50% tumoral regression was 
achieved in comparison with pre- chemotherapy sensitivity assay scan as evidenced by MRI. 
Patient 2 was found resistant to all treatments tested and following 6 cycles of Vincristine, 
Carboplatin, Cyclophosphamide, Etoposide, and Cisplatin in various combinations, the tumor of 
this patient rapidly progressed and proton beam therapy was recommended. As expected animal 
studies conducted with patient derived xenografts treated with chemotherapy sensitivity assay 
screened drugs recapitulated the clinical observation. This assay demonstrates that patients with 
the same histological stage and grade of cancer may vary considerably in their clinical response, 
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suggesting that chemotherapy sensitivity assay testing which measures the sensitivity of CSLCs 
as well as the bulk of tumor cells to a variety of chemotherapy agents could lead to more 





Although Ependymomas are the third most common type of brain tumor in children 
(following Astrocytoma and Medulloblastoma), they are relatively rare, with approximately 200 
cases diagnosed in the US each year (59,60). They account for 60% of all intramedullary tumors 
and 50% arise in the filum terminale (61).  
The treatment of Ependymoma can be challenging. The initial standard treatment for 
Ependymoma is surgery often followed by radiation therapy and chemotherapy. Although 
chemotherapy has been used extensively in children with Ependymoma, there is little clinical 
evidence that chemotherapy improves survival of children with this type of tumor. 
Chemotherapy is often reserved for patients with residual tumor after surgery and for children 
younger than 3 years of age in an attempt to delay radiation therapy (62).  
It is not entirely clear why there is not an improved survival with chemotherapy, but it is 
known that resistance to a variety of commonly used chemotherapeutic agents is common in 
Ependymoma (63). Therefore investigation and development of novel strategies and integrated 
therapies are required to find more effective treatments for this type of tumor.  
Patients with the same stage and grade of cancer may vary considerably in their clinical 
response and toleration of chemotherapy. Ineffective anticancer therapy can result in unnecessary 
toxicity and the development of resistant clones. The surviving cancer cells are often more 
resistant to therapy. Many attempts have been made over the years to develop an ex-vivo anti-
cancer test that could help discern the best treatment options for each individual patient while 
minimizing toxicity.  
Animal xenograft models have shown that only a subset of cancer cells within each tumor 
is capable of initiating tumor growth. This capability has been shown in several types of human 
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cancers, to include Ependymoma (64). This pool of cancer cells is operationally defined as the 
‘‘Cancer Stem-Like Cell’’ (CSLC) subset. According to the ‘‘cancer stem-like cell’’ theory, 
tumors are a complex, growing population of abnormal cells originating from a minority of 
CSLCs. These cells maintain stem-like characteristics in that they proliferate very slowly and 
have an inherent capacity to self-renew and differentiate into phenotypically heterogeneous, 
aberrant progeny (45,65-67). Unlike the bulk of tumor cells, CSLCs resist chemotherapy and 
radiation therapy and are responsible for tumor relapse and metastasis (66,67). 
Some Ependymoma express various markers of stemness, including CD133. In addition, 
relapsed tumors exhibit a gene expression signature constituted by up-regulated genes involved 
in the kinetochore (ASPM, KIF11) or in neural development (CD133, Wnt and Notch pathways) 
(68).  
Targeting CSLCs in addition to the bulk of other cancer cells within a tumor is a new 
paradigm in cancer treatment. This recent study shows that a Hydrodynamic Focusing Bioreactor 
(HFB) (Celdyne, Houston TX) selectively enriches CSLCs from cancer cell lines that can be 
used in a chemosensitivity assay (45). Further, using this strategy to optimize the enrichment of 
CSLCs from tumor biopsies has become essential to the development of the chemotherapy 
sensitivity assay, which measures the response of CSLCs and the bulk of tumor cells to 
chemotherapy to determine the most effective combination of anticancer drugs for malignant 
tumors of the nervous system.  
In this study it is reported for the first time, an investigation using the chemotherapy 
sensitivity assay to measure the sensitivity and resistance of CSLCs and bulk of tumor cells. It 
was performed on two biopsies cultured from human Ependymoma. These tumors were 
challenged with several chemotherapy agents which were also correlated to the response of 
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MATERIALS AND METHODS 
Patients 
Case 1 is a 21-year-old male patient diagnosed with intradural, intramedullary, and 
extramedullary anaplastic diffuse spinal Ependymoma, WHO grade III. Case 2 is a 5-month old 
female patient diagnosed with anaplastic WHO grade III Ependymoma. The chemotherapy 
sensitivity assay was performed after obtaining patient’s or guardian’s written informed consent 
in accordance with the ethical standards of the Helsinki Declaration (1964, amended most 
recently in 2008) of the World Medical Association. Any information, including illustrations, has 
been anonymized. Marshall University Institutional Review Board (IRB) has approved this 
research under the protocol #326290. Participants or guardians of participant (in case of a child 
participant) provided their written consent on an IRB approved informed consent form to 
participate in this study after being educated about the research protocol. Ethics committees/ IRB 
at Marshall University approved this consent procedure. For children participants to the study, 
written informed consent was obtained from the next of kin, caretakers, or guardians on behalf of 
the minors/children enrolled in the study. 
 
Single Cell Suspension and Primary Cell Culture 
Single-cell suspensions from the Ependymoma biopsies were prepared using the 
gentleMACS Dissociator (Miltenyi, Auburn, CA), and C Tubes using a standardized, semi-
automated protocol based on a combination of mechanical tissue disruption and incubation with 
a 50% solution of a 0.025% Trypsin and Accutase (Innovative Cell Technologies, San Diego, 
CA). Cells were serially plated in 24-well, 12-well, 6-well, 10-cm treated dishes and cultured to 
subconfluence in RPMI-1640 medium supplemented with 5% irradiated, heat inactivated, 
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defined fetal bovine serum (Thermofisher/Hyclone), and 50 U of penicillin and 5 mg of 
streptomycin/mL of medium (Thermofisher/Mediatech). 
 
Reagents 
Benzyl isothiocyanate (BITC) was purchased from Sigma Chemical Co. (St. Louis, MO). 
Bevacizumab (Avastin), Cisplatin, Oxaliplatin, Arabinoside-C, VP-16, Irinotecan (Camptosar, 
CPT-11), Busulfan, Methotrexate, were acquired as clinical grade chemotherapy agents from 
Edwards Cancer Center and St. Mary’s Hospital. 
 
Three-Dimensional Bioreactor CSCs Culture  
A Hydrodynamic Focusing Bioreactor (HFB) (Celdyne, Houston TX) was used as 
previously described to selectively proliferate CD133 (+) cancer stem-like cells (45). Culture 
media, oxygenation, speed, temperature and CO2 were kept constant for ten days. Cells were 
counted and 1x10 cells were placed in the rotating vessel set at 25 rpm with airflow set at 20%. 
Cells were then removed and counted again using trypan blue exclusion to determine cellular 
viability and cell number and plated in 96 wells for chemosensitivity testing. The cells were also 
incubated with florescent antibodies for phenotypic characterization (45). 
 
Cell Sorting 
Up to 1x10 cells were sorted by a magnetic-activated cell sorting (MACS) system, 
which consists of magnetic beads conjugated to an antibody against CD133 (Miltenyi, Auburn, 
CA). In brief, cells were harvested using 0.25% trypsin, pelleted and labeled with CD133/1 
biotin and CD133/2-PE. Cells were washed and labeled with anti-biotin magnetic beads, and 
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then passed through a magnetic column where CD133 (+) cells were retained, while unlabeled 
cells passed through the column. The CD133 (+) retained cells were eluted from the columns 
after removal from the magnet. Positive and negative cells were then analyzed by FACS for 
purity. 
 
Flow Cytometry Studies 
Cells were analyzed by the antigenic criteria using anti-CD34 (Milteny Biotech, Auburn, 
CA), -CD38 (Milteny Biotech, Auburn, CA), -CD44 (BD Bioscience, Sparks, MD), -CD117 
(Milteny Biotech, Auburn, CA), -CD133/2 (prominin1) (Milteny Biotech, Auburn, CA), -Oct3/4 
(BD Bioscience, Sparks, MD), and –Nanog (BD Bioscience, Sparks, MD). Briefly, cells were 
detached using 0.02% EDTA in PBS and pelleted (10 min at 1,000 rpm), washed in 0.1% BSA 
in 1X PBS at 4°C and incubated in a solution of 1 mg antibody +9 mL 0.1% BSA in 1X PBS. 
Cells were washed in the same solution once and were analyzed using a C6 Accuri flow 
cytometer (BD Biosciences, San Jose, CA). 
 
Chemotherapy Sensitivity Assay 
Sensitivity to chemotherapy was assessed using a viability assay (WST8) on 1x10³ cells 
plated in five replicas into 96-well plates. Briefly, equal number of bulk of tumor cells grown in 
monolayer and CSLCs grown in the bioreactor were counted and seeded separately in 96-well 
dishes and incubated at 37°C for 24 hours. The cells were then challenged with a one-hour pulse 
of a panel of anticancer drugs as chosen by the oncologist to mimic the average clinical 
chemotherapy infusion schedule.  
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To study the effect of BITC on chemosensitization of cancer cells to chemotherapy drugs, 
the cells were treated with an hour pulse 5–30 mM BITC followed by an hour of the various 
anticancer drugs. Each anticancer drug was tested in a range of doses including the clinically 
relevant dose. 
A WST8 assay was performed 48 hours following chemotherapy treatment to assess cell 
viability as previously described (69). A dose response chart was developed in which samples 
were scored as responsive (0–30% cell survival), intermediate (30–60% cell survival), and non-
responsive (60–100% cell survival). 
 
Limiting Dilution Tumorigenic Assay in Immune Deficient Mice 
A range of 1x10²; 1x10³; 1x10⁴; and 1x10⁵ Ependymoma cells from Patient 1 were 
injected subcutaneously in five athymic immunodeficient nude nu/nu mice per group. Briefly, an 
equal number of parental bulk of tumor cells grown in 2D monolayer, CD133 (+) three-
dimensionally grown in the hydrofocusing bioreactor, and CD133 (+) MACSorted CSLCs were 
injected with 100 mL of matrigel in the flank of NOD-Scid mice and compared to the growth of 
CD133 negative cells for three months. 
 
Animal Study  
All animal studies have been conducted following approval from the Marshall University 
IACUC, protocol #373017. The effects of chemotherapies screened in vitro by the chemotherapy 
sensitivity assay were tested on human tumor biopsies that were xenografted in the flank of a 
NOD-Scid mouse model. 1x10 Ependymoma cells were mixed to 100 uL of matrigel (BD 
Biosciences, San Jose, CA) injected subcutaneously in the flank of ten athymic, NOD.Cg- Prkdc 
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Scid ll2rgtm1wjl/SzJ immunodeficient mice (NOD-Scid)/group and were grown for 10 weeks or 
until 100 mm³. Mice were randomized in different treatment and control groups and 
chemotherapy was administered by intraperitoneal (i.p.) injections in 200 uL as follows in a 
period of four weeks: 1) Group #1, Control group with primary tumor cells injected into flank 
and receiving i.p. sterile saline injections. Group #2, Experimental group injected i.p. with the 
least effective chemotherapy as determined by the in vitro chemotherapy sensitivity assay. Group 
#3, Experimental group injected i.p. with the most effective chemotherapy as determined by the 
in vitro chemotherapy sensitivity assay. Group #4, Experimental group injected i.p. with the 
second most effective chemotherapy as determined by the in vitro chemotherapy sensitivity 
assay. Group #5, Experimental group injected i.p. with the most effective combinatorial 
chemotherapy as determined by the in vitro chemotherapy sensitivity assay.  
Chemotherapy doses for the animal study were calculated using a body surface area 
(BSA) normalization method (70) from the clinical dose and verified according to doses 
previously determined by a literature search. 
Animals were euthanized following the current guidelines established by the latest Report 




Statistical analysis was performed using the IBM SPSS statistical software. The results 
for each variant in the different experimental designs represent an average of three different 
experiments. The data of five measurements were averaged; the coefficient of variation among 
these values never exceeded 10%. Mean values and standard errors were calculated for each 
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point from the pooled normalized to control data. Statistical analysis of the significance of the 
results was performed with a one-way ANOVA. P values of less than 0.05 were considered 











Figure 5. MRI Images and H&E Staining of the Anaplastic Ependymoma Case 1 at Presentation. 
A) Magnetic Resonance Imaging (MRI) of the cervical spine showing the presence of an enhancing mass, 
which extends from mid C5 to inferior C7 (4.5 in length x 1.0 x 2.0 in cephalocaudal and anteroposterior 
dimension) and causing cord compression. 
B) MRI of the thoracic spine showing an enhancing lesion at T2–3 (1.5 in length x 0.6 x 0.6 cm in 
anteroposterior and transverse dimension) with several other smaller nodular masses, best seen on the T2 
weighted sequence, which extended throughout the thoracic level to T11.  
C) Hematoxylin and Eosin staining of a tumor section showing an overall predominant dense cellular 
component, with primitive nuclear features, mitotic activity, necrosis and vascular proliferation. The 
presence of well formed, obvious perivascular pseudorosettes (with vasocentric pattern, perivascular 
nuclear-free zones, and classic thin glial processes radiating to/from the vessel wall) were found 
supportive of the diagnosis of intradural, extramedullary anaplastic diffuse spinal Ependymoma, WHO 





Ependymoma Patient 1  
A physically active 17-year-old male presented in October 2005 with paresthesia in his 
feet and a rather severe perceptive loss. This became progressively worse in December 2005 
going up his legs with rather severe numbness in the right leg and pain in his left leg, from the 
mid-thigh down to the mid-calf medially. On examination he had no focal weakness throughout 
his upper and lower extremities. He had hypoalgesia with partial sensory level in the upper 
thoracic spine down. He also had severe proprioception loss in his feet and toes. Magnetic 
resonance imaging (MRI) of the cervical spine showed the presence of an abnormal enhancing 
mass, which extended from mid C5 to inferior C7 (4.5 in length x 1.0 x 2.0 in cephalocaudal and 
anteroposterior dimension) that caused cord compression (Figure 5A). MRI of the thoracic spine 
showed an enhancing lesion at T2–3 (1.5 in length x 0.6 x 0.6 cm in anteroposterior and 
transverse dimension) with several other smaller nodular masses, best seen on the T2 weighted 
sequence, which extended throughout the thoracic level to T11 (Figure 5B).  
The patient received a laminectomy in December 2005 at C5, C6, and C7 with partial 
resection of the tumor under microscope using microsurgical techniques. Following surgery, the 
patient was treated with radiation and temozolomide. Morphological analysis of the histology 
sections stained with Hematoxylin & Eosin showed an overall predominant dense cellular 
component, with primitive and pleomorphic nuclei, increased mitotic rate and apoptosis, and foci 
with microvascular proliferation. The presence of well formed, obvious perivascular 
pseudorosettes (with vasocentric pattern, perivascular nuclear-free zones, and classic thin glial 
processes radiating to/from the vessel wall) were found  supporting the diagnosis of anaplastic 
diffuse spinal Ependymoma, WHO grade III.  
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Figure 5C shows the hematoxylin and eosin staining of a tumor section at diagnosis in 
2005. Sections of the tumor were evaluated by immunoperoxidase techniques with appropriate 
staining control sections. The tumor showed positive staining with antibodies to neuron specific 
enolase, vimentin, S-100, and GFAP. Weak staining occurred with the antibodies against actin. 
Focal staining occurred with antibodies to epithelial membrane antigen, cytokeratin AE1/AE3, 
and synaptophysin. The tumor was negative for leukocyte common antigen, desmin, and 
myogenin. In addition, a section stained with PAS showed a focal PAS-positive fibrillar material. 
Sections and tumor block were also sent to the Biopathology Center (BPC) of the Children’s 
Oncology Group (COG) where two neuropathologists independently reviewed the case and 
confirmed the diagnosis of Anaplastic Ependymoma, WHO grade III.  
Following recurrence and progression, the patient received complex chemotherapy 
regimen in January 2006 and March 2006 with Cyclophosphamide, Thalidomide, Celecoxib 
followed by Etoposide, Thalidomide and Celecoxib. Chemotherapy treatment was concluded in 
September of 2006, but in August of 2007 patient had tumor regrowth at T7–T8 for which he 
underwent robotic radiosurgery treatment. The patient had another debulking surgery in April of 
2008, but later in December of 2008 he had progressive numbness in his legs along with back 
pain with MRI showing recurrence in the surgical area (Figure 6A) as well as the lumbar spine. 




Figure 6. MRI Images of Cervical and Thoracic Spine of Ependymoma Case 1. 
A) 2009 MRI of the cervical spine showing recurrence in the surgical area. B) 2009 MRI of the thoracic 
spine showing progression of the main lesion measuring 23.9 mm, and the appearance of several other 
smaller lesions. C and D) 2010 MRI of the cervical and thoracic spine showing tumor regression 




In March 2009 because of progression of the disease he had a thoracic laminectomy and 
resection of the intradural intramedullary tumor. He had severe spinal compression and began 
having weakness in his legs. Due to further recurrence, the patient then had another debulking 
surgery in July of 2009. He also received Oxaliplatin and Etoposide treatment in July and August 
2009, but the tumor progressed even more (Figure 6B). Appropriate informed consent was 
signed and at the time of the debulking surgery of July 2009, a sterile biopsy was taken to assess 
the sensitivity of the tumor cells (bulk of tumor and CSLCs) toward standard-of-care 
chemotherapy drugs using the chemotherapy sensitivity assay. The biopsy was placed in RPMI-
1640 sterile media and tissue was dissociated in the laboratory into a single-cell suspension with 
the use of a GentleMACS tissue dissociator (Miltenyi, Aubourn, CA). The single-cell 
Ependymoma suspension was plated in RPMI-1640 in the presence of 5% irradiated, heat 
inactivated, defined fetal bovine serum, streptomycin and penicillin and cells were cultured as a 
monolayer for 15 days. Cells were immunophenotyped by flow cytometry using antibodies 
against CD34, CD38, CD44, CD117, CD133, OCT3/4, and Nanog. 
The Ependymoma cells were found positive to OCT3/4 (2.73%), Nanog (0.95%), CD133 
(49.93%), CD117 (36.81%), and CD44 (20.39%) when compared to an isotype control antibody 
(Figure 7 A-E). A double staining of CD34 and CD38 showed the presence of 1.88% of the cells 
CD34+/CD38+, and 78.4% CD34+/CD38- cells (Figure 7F). To expand the CSLC population of 
CD133+ cells from the Ependymoma primary culture, the Ependymoma cells were cultured as 
previously described (45). 1x10 of the Ependymoma cells from a monolayer primary culture 
were grown for ten days using Hydrodynamic Focusing Bioreactor (HFB) (Celdyne, Houston, 
TX) (45). The Ependymoma cells cultured in the bioreactor formed cell clusters (Figure 8A) 
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which were expanded 14.7 fold (Table 1) and appeared to be 95.93% CD133 positive after 10 
















































Figure 7. Characterization of the Primary Ependymoma Cell Culture and of the Enriched CSLCs of Case 
1. 
A-F) Immunophenotype conducted using: A) OCT3/4 antibody; Left panel: isotype antibody (bulk of 
tumor cells); Center panel: specific antibody (bulk of tumor cells); Right panel: specific antibody 
(enriched CSLCs). B) Nanog antibody; Left panel: isotype antibody (bulk of tumor cells); Center panel: 
specific antibody (bulk of tumor cells); Right panel: specific antibody (enriched CSLCs). C) CD133 
antibody; Left panel: isotype antibody (bulk of tumor cells); Center panel: specific antibody (bulk of 
tumor cells); Right panel: specific antibody (enriched CSLCs). D) CD117 antibody; Left panel: isotype 
antibody (bulk of tumor cells); Center panel: specific antibody (bulk of tumor cells); Right panel: specific 
antibody (enriched CSLCs). E) CD44 antibody; Left panel: isotype antibody (bulk of tumor cells); Center 
panel: specific antibody (bulk of tumor cells); Right panel: specific antibody (enriched CSLCs). F) 
Double labeling with CD34 and CD38 antibodies; Panel on left: isotype antibody (bulk of tumor cells); 





Figure 8. CD133 (+) Ependymoma Cells from Case 1 Grown in a Hydrofocusing Bioreactor form 
Xenografts in nude Mice. 
A) Contrast phase image of a cluster of enriched CSLCs following seven-days of culture in a 
hydrofocusing bioreactor. B) Immunodeficient nude mice (nu/nu) injected with 1x10² Ependymoma cells 
MACSorted CD133(+) cells or CD133(+) Ependymoma cells grown in the hydrofocusing bioreactor, 
with the aid of 100 mL of matrigel in the flank formed a tumor within three months compared to 
CD133(2) cells. doi:10.1371/journal.pone.0105710.g003 
 
Table 1. Enrichment of CD133+ CSLCs using a hydrofocusing bioreactor. 
 
 
To verify the tumor-initiating capacity of the HFB grown cells, five immune deficient 
nude mice/group were injected with a range of 1x10², 1x10³, 1x10⁴, and 1x10⁵ cells grown in the 
HFB (96% CD133+) and compared their growth to an equal number of CD133(+) MACSorted 
cells and CD133(2) cells for three months. It was observed that both 1x10² MACSorted CD133 
(+) cells or the CD133 (+) from the bioreactor grew in all the immune deficient mice injected 
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and formed a palpable tumor within 12 weeks (Figure 8B). To perform the chemotherapy 
sensitivity assay a comparable number of cells (1x10⁵) from the bulk of tumor cells grown as a 
2D monolayer or CSLCs enriched in the bioreactor (45) were separately plated into 96 wells 
plates (n-5 replicas) and were treated for an hour with a series of anticancer drugs at a range of 
concentrations including the clinically relevant dosage (Table 2). Chemotherapy sensitivity assay 
was performed using a panel of drugs comprised of Cisplatin, Oxaliplatin, Arabinoside-C, VP-
16, Busulfan, Methotrexate, Irinotecan, and Bevacizumab as chosen by the treating oncologist. 
Sensitivity to chemotherapy was assessed at 48-hours by WST8 viability assay. It was 
categorized as follows based on the percentage of non-viable cells: responsive (0–40% cell 
survival), intermediate (40–70% cell survival), and non-responsive (70–100% cell survival). The 
WST8 assay was conducted three separate times with n=5 well replicas/drug/dose each time. 
 
Table 2. Clinical dose and calculated in vitro doses of the various chemotherapies. 
 
Results of the chemotherapy sensitivity assay (Figure 9) showed that the Ependymoma 
cells grown in monolayer and representing the bulk of tumor cells were sensitive to clinically 
relevant doses of Cisplatin, Irinotecan, Busulfan, and a combination of Irinotecan and 
Bevacizumab in a statistically significant manner (p< 0.05). Interestingly, the CSLCs were 
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sensitive to a combination of Irinotecan and Bevacizumab (p< 0.05), intermediately sensitive to 
Cisplatin, and Irinotecan, but not sensitive to Busulfan. On the other hand, both the CSLCs and 
the bulk of tumor cells were not responsive to Methotrexate, Oxaliplatin, Arabinoside-C, and 
VP-16 (Figure 9). Because of the lack of response to an Oxaliplatin and Etoposide management 
given in August 2009 (Figure 6B) (which was started prior to receiving the results from the 
chemotherapy sensitivity assay), in October 2009 the patient underwent a treatment with 
Bevacizumab and Irinotecan, which was administered every two weeks for six months. In a 
follow-up MRI scan in May 2010 the patient showed initial disease regression remaining free 
from disease progression for 18 months (Figure 6C and D). This corresponded to the longest 
disease progression free period observed in this patient without major de-bulking surgery. 
Recurrence of tumor growth after 18 months of disease free progression led us to explore novel 
therapeutic approaches for the treatment of this patient’s cancer. In this regard, combination 
chemotherapy was investigated in order to identify natural compounds that may increase the 






















Figure 9. Diagram of Chemotherapy Sensitivity Assay to Assess the Sensitivity to Chemotherapy of 
Cancer Cells or CSLCs of Ependymoma Case 1 Using a WST-8 Assay. 
Bulk of tumor cells or CSLCs were plated with 1x10³ cells in each well of a 96-well plate. The treatments 
were replicated five times in 96-well plates and were challenged for a one-hour pulse with a panel of 
anticancer drugs indicated by the oncologist. A WST-8 assay was performed 48-hours following 
chemotherapy treatments to assess cell viability. The data above is plotted in bar graph and results were 
determined as responsive (0–40% cell viability), moderately responsive (40–70% cell viability), and non-
responsive (70–100% cell viability). Light grey bars represent sensitivity of CSLCs to chemotherapy with 
respect to negative untreated control cells. Dark grey bars represent sensitivity of bulk of tumor cells to 
chemotherapy with respect to negative untreated control cells. Anticancer drugs tested indicated at the 
bottom of the diagram. Statistical analysis of the results was performed using one-way ANOVA. 
Asterisks indicate p values of less than 0.05. doi:10.1371/journal.pone.0105710.g004 
 
Benzyl isothiocyanate (BITC) has been shown (71,72) to increase the chemosensitivity of 
cancer cells. This study recently observed (Figure 10) that BITC increases specifically the 
chemosensitivity of CD133 positive cancer cells. Because the primary Ependymoma cells of 
Patient 1 displayed a high percentage of cells positive to CD133, the hypothesis that BITC could 
increase their chemosensitivity to Irinotecan and Bevacizumab was tested. Increasing 
concentrations of BITC ranging from 2.5 mM to 20 mM decreased the viability of CD133(+) 
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Ependymoma cells of Patient 1 from 90% to 62% in a statistically significant manner (Figure 
11A). Chemotherapy sensitivity assay also determined that the combination of Irinotecan and a 
non-toxic concentration of 10 mM BITC reduced the viability of the Ependymoma cells from 
60% to 40% (over 40% more chemosensitive compared to non BITC treated cells) (Figure 11B). 
Additionally, the combination of Irinotecan and Bevacizumab with BITC reduced even further 
the viability of the Ependymoma cells to 30% (Figure 6B). The patient was treated with 
Irinotecan and Bevacizumab, but this time with the combination of two capsules/day of a Triple 
Action Cruciferous Vegetable Extract containing high concentration of BITC (LifeExtension, 
http:// www.lef.org), for two months. Following the combination therapy of Irinotecan, 
Bevacizumab and the supplement of cruciferous vegetable extract there was a 4 cm regression 
(which corresponds to a 50% regression) of the lesions in the thoracic and the cervical area 
[compare Figure 6C (at recurrence) to Figure 11D (following therapy)]. Additionally, it was 
reported that the patient was able to tolerate the entire course of Irinotecan and Bevacizumab 













Figure 10. Diagram of Chemotherapy Sensitivity Assay to Assess the Sensitivity to BITC and 
Chemotherapies of Cancer Cells or CSLCs of Ependymoma Case 1. 
1x10³ bulk of tumor cells or CSLCs plated in five replicas into 96-well plates were treated with 10uM of 
BITC for 24 hours before being challenged for a one-hour pulse with CPT-11, Avastin or a combination 
of the two. A WST-8 assay was performed 48 hours following BITC treatments to assess cell viability. 
Data is plotted in bar graph as responsive (0–40% cell viability), moderately responsive (40–70% cell 
viability), and non-responsive (70–100% cell viability). Light grey bars represent sensitivity of CSLCs to 
chemotherapy with respect to negative untreated control cells. Dark grey bars represent sensitivity of bulk 
of tumor cells to chemotherapy with respect to negative untreated control cells. Anticancer drugs tested 
indicated at the bottom of the diagram. Statistical analysis of the significance of the results was performed 
with a one-way ANOVA. Single asterisks indicate p values of less than 0.05. Double asterisks indicate p 










Figure 11. Diagram of Chemotherapy Sensitivity Assay and MRI Images of Cervical and Thoracic Spine 
following Integrated Therapy of Ependymoma Case 1. 
A) 1x10³ CSLCs plated in five replicas into 96-well plates were challenged for a one-hour pulse with 2.5, 
10, and 20 mM BITC. A WST-8 assay was performed 48 hours after treatments to assess cell viability. B) 
1x10³ CSLCs plated in five replicas into 96-well plates were challenged for a one-hour pulse with 10 mM 
BITC followed by a one-hour pulse with 0.5 mM CPT-11. A WST-8 assay was performed 48 hours 
following chemotherapy treatment to assess cell viability. Data is plotted in bar graph as responsive (0–
40% cell viability), moderately responsive (40–70% cell viability), and non-responsive (70–100% cell 
viability). Light grey bars represent sensitivity of CSLCs to chemotherapy with respect to negative 
untreated control cells. Dark grey bars represent sensitivity of bulk of tumor cells to chemotherapy with 
respect to negative untreated control cells. Statistical analysis of the significance of the results was 
performed with a one-way ANOVA. Asterisks indicate p values of less than 0.05. C) 2012 MRI of the 
cervical and thoracic spine showing recurrence after an 18 months progression free period. D) 2012 MRI 
of the cervical spine showing marked tumor regression of the thoracic spine lesion following combined 




The efficacy of chemotherapies screened in vitro by the chemotherapy sensitivity assay 
were tested on the Ependymoma cells of Patient 1 that were xenografted in a NOD-Scid mouse 
model (Figure 12 A and B). Ten athymic NOD-Scid mice were injected in the flank with 1x10 
Ependymoma cells mixed to 100 uL of matrigel (BD Biosciences, San Jose, CA) and tumors 
were grown for ten weeks or until 100 mm³. Randomized mice were treated with weekly 
intraperitoneal (i.p.) injections of the different treatment arms for four weeks and were observed 
for four more weeks. Group #1 serving as a control received i.p. sterile saline injections. Groups 
#2–5 were the experimental groups, which received i.p. injections of the least effective 
chemotherapy, or the most effective, the second most effective, and the most effective 
combinatorial chemotherapy, as determined by the in vitro chemotherapy sensitivity assay. 
Interestingly, the tumor xenografts in the Scid mice injected with the least effective 
chemotherapy as determined by the in vitro chemotherapy sensitivity assay grew faster than 
saline control injected mice (Figure 12A). As expected, tumor regression was observed in Scid 
mice treated with the most effective, the second most effective, and the most effective 
combinatorial chemotherapy as determined by the in vitro chemotherapy sensitivity assay, 
confirming the clinical observation that Irinotecan and Bevacizumab are more effective 
anticancer drugs in this individual patient. Mice weight was measured weekly (Figure 12B). 
The hypothesis was tested further by mice that were failing a chemoresistant treatment 
could be rescued by switching them to a more sensitive treatment as determined by the in vitro 
chemotherapy sensitivity assay. Mice that were failing an Oxaliplatin therapy regimen were 
taken off Oxaliplatin at week 16 and were treated for four weeks with a combination of 
Irinotecan and Bevacizumab. As expected, mice treated with Irinotecan and Bevacizumab 
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showed a regression of the xenografted tumor compared to the control mice injected with saline 








Figure 12. Mean Tumor Volume and Mean Tumor Weight of Patient Derived Xenografts (Ependymoma 
Case 1) Treated with i.p. Injection of Anticancer Drugs. 
A) Line diagram of the mean volumes in mm³ (±SD) from week 6–16 of ten patient derived xenografted 
tumors in NOD-Scid mice following four weeks of treatment with various anticancer drugs. The mean 
tumor volumes are indicated on the ordinate. Asterisks indicate weeks in which treatment was performed. 
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On the right are indicated the different treatment arms. PBS: saline solution, negative control. OXA 
(Oxaliplatin); Avastin (Bevacizumab); CPT-11 (Irinotecan); CDDP (Cisplatin). B) Line diagram of the 
mean weight in grams (±SD) of ten NOD-Scid mice-bearing patient derived xenografted tumors 
following four weeks of treatment with various anticancer drugs. The mean tumor weights are indicated 
on the ordinate. Asterisks indicate weeks in which treatment was performed. On the right are indicated the 
different treatment arms. PBS: saline solution is negative control. OXA (Oxaliplatin); Avastin 
(Bevacizumab); CPT-11 (Irinotecan); CDDP (Cisplatin). C) Line diagram of the mean volumes in mm³ 
(±SD) from week 16 to 20 of the ten patient derived xenografted tumors in NOD-Scid mice that failed 
Oxaliplatin therapy (weeks 6–16 in panel A), following three weeks of treatment with Irinotecan and 
Bevacizumab. The mean tumor volumes are indicated on the ordinate. Asterisks indicate weeks in which 
treatment was performed. On the right are indicated the different treatment arms. PBS: saline solution, 
negative control. OXA (CPT11+Avastin): mice that failed Oxaliplatin and were then treated with 
Irinotecan and Bevacizumab. D) Line diagram of the mean weight in grams (±SD) of the ten NOD-Scid 
mice-bearing patient derived xenografted tumors following three weeks of treatment with Irinotecan and 
Bevacizumab. The mean tumor weights are indicated on the ordinate. Asterisks indicate weeks in which 
treatment was performed. On the right are indicated the different treatment arms. PBS: saline solution, 
negative control. OXA (CPT11+Avastin): mice that failed Oxaliplatin and were then treated with 




Ependymoma Patient 2   
Patient 2 was a five-month-old female with an aggressive brain tumor that was surgically 
removed in April 2012. The tumor was diagnosed as an Anaplastic Ependymoma, WHO grade 
III with low-grade mitosis-poor areas and high cellular tissue with mitosis and high MIB-1 rate. 
A biopsy from the surgically removed tumor was placed in RPMI-1640 sterile media and 
the tissue was dissociated in the laboratory into a single-cell suspension with the use of a 
GentleMACS tissue dissociator (Miltenyi, Aubourn, CA) as done in the previous case. The 
single-cell Ependymoma suspension was plated in RPMI-1640 in the presence of 5% irradiated, 
heat inactivated, defined fetal bovine serum, streptomycin and penicillin and cells were cultured 
as a monolayer for 15 days. Cells were immunophenotyped by flow cytometry using antibodies 
against CD34, CD38, CD44, CD133, Nanog, and CXCR4. The Ependymoma cells were found 
positive to Nanog (13%), CD133 (47.5%), CD44 (65.5%), and CXCR4 (89.7%) when compared 
to an isotype control antibody. A double staining of CD34 and CD38 showed the presence of 
4.6% of the cells CD34+/CD38+, and 47.3% CD34+/CD38- cells. 
The chemotherapy sensitivity assay performed on the bulk of the Ependymoma cells and 
on the CSLCs showed resistance to all of the tested chemotherapy drugs (Figure 13). Patient 2 
received complex chemotherapy with six cycles of Vincristine, Carboplatin, Cyclophosphamide, 
Etoposide, and Cisplatin in various combinations, however the tumor rapidly progressed and 
proton beam therapy was recommended. The tumor did not respond to the various anticancer 







Figure 13. Diagram of Chemotherapy Sensitivity Assay to Assess the Sensitivity to Chemotherapy of 
Cancer Cells or CSLCs Using a WST-8 Assay on Ependymoma Case 2. 
1×10³ bulk of tumor cells or CSLCs plated in five replicas into 96-well plates were challenged for a one-
hour pulse with a panel of anticancer drugs indicated by the oncologist. A WST-8 assay was performed 
48 hours following chemotherapy treatments to assess cell viability. Data is plotted in bar graph as 
responsive (0–40% cell viability), moderately responsive (40–70% cell viability), and non-responsive 
(70–100% cell viability). Light grey bars represent sensitivity of CSLCs to chemotherapy with respect to 
negative untreated control cells. Dark grey bars represent sensitivity of bulk of tumor cells to 
chemotherapy with respect to negative untreated control cells. Anticancer drugs tested indicated at the 
bottom of the diagram. Statistical analysis of the significance of the results was performed with a one-way 





Treatment for Ependymoma is often a combinatorial approach that includes surgery, 
radiation therapy, and chemotherapy. Although chemotherapy has been used extensively in the 
treatment management of Ependymomas, this therapeutic modality is often reserved for patients 
with residual tumor after surgery and for children younger than three years of age in an attempt 
to delay radiation therapy. Recently, the role of chemotherapy in the treatment of Ependymoma 
has diminished because (1) chemotherapy fails to delay the need for radiation therapy for a 
meaningful period of time; (2) tumors that progress during chemotherapy do not respond as well 
to subsequent irradiation; and (3) the combination of chemotherapy and irradiation does not 
improve overall survival (59,73). 
It is not entirely clear why there is not an improved survival with chemotherapy (63), 
therefore investigation and development of novel strategies and integrated therapies are required 
to find more effective treatments for this type of tumor. 
One of our patients was diagnosed with recurring undifferentiated intradural-
extramedullary spinal Ependymoma, WHO grade III, with a distinctive sensitivity to 
chemotherapy who has been followed up for five years following chemotherapy sensitivity 
assay. The second patient was also diagnosed with recurring Ependymoma, WHO III but was 
found not sensitive to any of the chemotherapies tested and rapidly progressed. 
Resistance to chemotherapy severely compromises its effectiveness. The development of 
resistance is a major problem for patients, researchers, and clinicians who rely on conventional 
cytotoxic agents for the treatment of cancer. 
Despite the fact that several treatments for Ependymoma are currently available, this 
remains a poorly treated disease (74-78). Surgery plus postoperative radiotherapy represents the 
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standard treatment for patients with grade III (Anaplastic) Ependymomas (78,79). Additionally, 
surgery has been demonstrated to be associated with significant improvements in overall survival 
time for patients with all stages of ependymal tumors (80-84); however, a total resection is not 
always achieved. Overall prognosis is improved when the entire tumor can be removed and there 
are no other neural axis metastases (85). Therefore, in cases in which the Ependymoma is 
multifocal, metastatic, incompletely resected, or particularly aggressive, it is imperative to find 
the most effective alternative treatment to surgery available. 
Administration of ineffective anticancer therapy is associated with unnecessary toxicity 
and development of resistant clones. Each time patients are treated, they have a chance of relapse 
and their cancer may become more resistant to therapy. Presently used anticancer drugs have a 
high rate of failure and cell culture chemotherapy testing is being used to identify which drugs 
are more likely to be effective against a particular tumor type. Measuring the response of the 
tumor cells to drug exposure is valuable in any situation in which there is a choice between two 
or more treatments. In virtually all situations in cancer chemotherapy, the goal is cure or 
palliation. This kind of testing can assist in individualizing cancer therapy by providing 
information about the likely response of an individual patient’s tumor to proposed therapy. Many 
attempts have been made over the years to develop an ex-vivo anti-cancer test that can provide 
clinically relevant treatment information, but all the efforts have been directed toward the bulk of 
tumor cells (86-92). 
In the recent past, chemotherapy testing has been performed on cancer cells from patients 




Knowing which chemotherapy agents the patient’s bulk of tumor cells, as well as the 
CSLCs, are resistant to is very important. Then, these options can be eliminated, thereby 
avoiding the toxicity of ineffective agents. Choosing the most effective agent can help patients to 
avoid the physical, emotional, and financial costs of failed therapy and experience an increased 
quality of life.  
The chemotherapy sensitivity assay used in this study measures for the first time the 
survival of CSLCs and bulk of tumor cells cultured from human cancer biopsies to 
chemotherapeutic agents. The advantage of the chemotherapy sensitivity assay is to aid the 
oncologists in selecting the most appropriate chemotherapy regimen on an individual basis 
especially when a number of equivalent options are available. The chemotherapy sensitivity 
assay allows various available chemotherapy drugs, which are part of standard of care to be 
tested for efficacy against the cancer stem cells, as well as the bulk of tumors. 
For Patient 1, affected by a recurring anaplastic Ependymoma, the chemotherapy 
sensitivity assay determined on both bulk of tumor cells and CSLCs, that the most effective 
treatments were either Irinotecan and Bevacizumab or Cisplatin. Interestingly, although the 
entire regimen containing Irinotecan and Bevacizumab could not be completed, the patient 
showed an initial regression of the disease and remained free from disease progression for 18 
months, which corresponded to the longest disease progression free period in this patient. 
Following up on the recurrence after the 18 month of progression free interval observed, 
repeated testing was performed using the chemotherapy sensitivity assay on the combination of 
several drugs and nutritional supplements, among which Benzyl isothiocyanate (BITC). 
Numerous studies have indicated that Isothiocyanates (ITCs) induce robust anti-cancer effects 
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(72,99,100). ITCs are derived naturally from glucosinolates, which are found at high 
concentrations in vegetables from the Cruciferae family (71,72).  
Cruciferous vegetables, which produce ITCs, include broccoli, Indian cress, cabbage, 
Brussel sprouts, and watercress (101). ITCs are of interest as anticancer molecules because of 
their ability to target many of the aberrant pathways associated with cancer development. 
However, among the numerous ITCs identified, only a few of them appear to have anti-
carcinogenic properties (102). 
Interestingly, BITC has been previously shown to increase the chemosensitivity of bulk 
of tumor cells (71,72), but not of CSLCs. In this study it has been observed that BITC can 
increase specifically the chemosensitivity of cells that are highly positive for CD133 (data not 
shown), a marker used to identify CSLCs in tumors of the nervous system. Since the primary 
Ependymoma cells of Patient 1 displayed a high percentage of cells positive to CD133, it was 
advantageous to do further testing of the hypothesis that BITC could increase the patient’s 
chemosensitivity. 
Interestingly, as demonstrated here, for the first time, that the combination of Irinotecan 
and BITC increased the chemosensitivity of the bulk of tumor cells and of the CSLCs cultured 
from the Ependymoma of Patient 1. There was a clinically significant regression of the lesion in 
the cervical area as well as regression of other lesions at the thoracic level following a combined 
treatment with Irinotecan, Bevacizumab, and BITC. 
Noteworthy and as expected, regression was observed of the NOD-Scid mice xenografts 
treated with the most effective, the second most effective, and the most effective combinatorial 
chemotherapy as determined by the in vitro chemotherapy sensitivity assay. In a model of patient 
derived xenografts this confirms the clinical observation that Irinotecan and Bevacizumab are 
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more effective anticancer drugs for this individual patient. Interestingly, the tumor xenografts in 
the Scid mice injected with the least effective chemotherapy as determined by the in vitro 
chemotherapy sensitivity assay grew faster than saline control injected mice. It is not known why 
the tumor xenografts in mice injected with Oxaliplatin grew faster than saline control injected 
mice, but speculated that because the patient was treated with Oxaliplatin prior to the 
chemotherapy sensitivity assay biopsy, it had selected cellular clones that are resistant to it and 
that manifest a growth advantage in its presence. 
Furthermore, mice that did not show regression to Oxaliplatin treatment, which mimics 
the clinical scenario of this particular patient, were rescued by switching them to a more effective 
treatment (Irinotecan and Bevacizumab) as determined by the in vitro chemotherapy sensitivity 
assay. As expected, in this rescue animal model the mice treated with a combination of 
Irinotecan and Bevacizumab showed a regression of the patient derived xenografted tumors 
compared to control mice injected with saline solution confirming once again the previously 
observed clinical data. 
Unfortunately, the second case of Ependymoma presented could not benefit from any 
combined therapy that was proposed indicating that although affected by the same type of tumor 
response to chemotherapy was different. 
This is the first report on the clinical relevance of this novel chemosensitivity assay that 
measures the sensitivity of bulk of tumor cells and CSLCs to chemotherapy, which has the 
objective to decrease unnecessary toxicity while increasing the benefit of cytotoxic therapy for 
patients affected by malignant tumors. 
Although the chemotherapy sensitivity assay results on these two cases of Ependymoma 
showed clinical relevance, a larger study with different histological tumor types is needed to 
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determine the prognostic accuracy of this assay. This laboratory is currently conducting a brain 
and spine malignant tumor phase-I clinical trial in which 33 patients have accrued in the past 
three years to study the feasibility of this new assay in predicting the most effective 
chemotherapy regimen to improve patients’ outcomes by assessing the vulnerability to 








Among the different types of central nervous system (CNS) tumors, glioblastoma 
multiforme (GBM) is the most aggressive and malignant primary brain tumor, exhibiting the 
highest mortality rate among the glioma subtypes, with a median survival of 14 months. GBM is 
persistently chemoresistant with substantial rates of reoccurrence. Most patients with GBM are 
treated with surgery followed by chemo-radiation therapy either at the time of initial diagnosis or 
at tumor recurrence.  
This study was designed to investigate an in vitro chemotherapy sensitivity assay, which 
measures the sensitivity of CSLCs as well as the bulk of tumor cells to a variety of chemotherapy 
agents for two Glioblastoma (GBM) patients. Patient 1 was a 56-year old male affected by a 
GBM IDH-1 mutant. This patient was found 50% sensitive to the treatment of Temodar (TMZ) 
on the bulk of the tumor, but resistant to TMZ when treating the CSC population. Six months 
after initial therapy (surgery, TMZ and radiation) a recurrence was observed. Patient 2 was a 35-
year old male with GBM IDH-1 wild-type. This patient was also treated with surgery followed 
by TMZ and radiation and at the six months follow up was found in remission. This event was 
predicted by the chemotherapy sensitivity assay that indicated a response of both CSLC and Bulk 
of tumor cells to TMZ.  
The results of the in vitro assays were confirmed by the use of mice bearing patient 
derived xenografts treated with the drugs screened by the chemotherapy sensitivity assay. The 
animal data was found to be in accordance with the data from both the patients’ outcome and the 
in vitro studies. This assay demonstrated again that patients with the same histological stage and 
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grade of cancer may not always respond to the same standard-of-care clinical treatment, 
suggesting that a chemotherapy sensitivity assay which measures the sensitivity of CSLCs as 
well as the bulk of tumor cells to a variety of chemotherapy agents could lead to more effective 






Glioblastoma (GBM) or WHO grade IV malignant glioma is diagnosed in about 10,000 
patients a year, making it the most common primary brain cancer in adults (46,52,103-105). 
Standard treatment usually consists of surgery followed by chemo-radiotherapy allowing for an 
average survival rate of only 14 months (3,52,103-108). The first line chemotherapeutic agent 
used is an oral medication called Temozolomide (Temodar, TMZ); it is an alkylating agent, 
disrupting DNA replication (3,6,52,104-107). 
Though advancements have been made in the treatment of GBM most patients have 
recurrence within a year (107). This poor prognosis has been associated with GMB 
heterogeneity, and the CSLC that initiate and maintain this disease (3,46,52,104). Several studies 
have identified biomarkers of anticancer drug resistance as well as tumor initiation 
(3,6,46,52,104). The subpopulation of CD133 positive cells has been shown to contain tumor 
initiator cells for GBM (3,46). This evidence supports the Cancer Stem Cell Hypothesis, and 
indicates that targeting this population would lead to novel treatments that significantly improve 
patient survival (46,52). 
There is an indication that some factors of the patient that may influence the survival rate 
and treatment resistance in patients include the status of the IDH1 gene and the methylation 
status of the O6-methylguanine-DNA-methyltransferase gene (MGMT) (3,6,108). The IDH-1 
gene encodes for cytosolic NADP+-dependent isocitrate dehydrogenase, which is involved in the 
control of oxidative cellular damage. It has been found that patients that have a mutation in the 
IDH-1 gene have better prognosis (108).  The IDH-1 gene encodes for an enzyme located in the 
cytoplasm and in peroxisomes that catalyzes the oxidative carboxylation of isocitrate to α-
ketoglutarate, which allows the reduction of NADPH. The production of NADPH is essential for 
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the regeneration of reduced glutathione, which functions as the main antioxidant in mammalian 
cells and promotes resistance to apoptosis.  IDH-1 therefore plays a prominent protective role 
against oxidative damage induced by ROS via the regeneration of reduced glutathione (109).  
In this context, mutation of IDH-1 appears paradoxical: on one hand, mutant IDH-1 cells 
may be more sensitive to genetic instability caused by an oxidative environment, and thus IDH-1 
mutations may contribute to tumor development, but on the other hand, mutant IDH-1 cells are 
less protected against oxidative cellular damage (109). 
This study investigated the chemosensitivity of Bulk of tumor cells and CSLC in two 
primary cell lines generated from two patients who were newly diagnosed with GBM and never 
treated before. GBM Patient 1 was found IDH-1 mutant and in GBM Patient 2, IDH-1 was found 





MATERIALS AND METHODS 
 
Cell Culture and Reagents 
 All cell culture was performed using previously established methods (50). All clinical 




Case 1 is a 56-year-old male patient diagnosed with an IDH-1 mutant GBM.  Case 2 is a 
35-year-old male with a IDH-1 wild type GBM. Chemotherapy sensitivity assay was performed 
after obtaining patient’s written informed consent in accordance with the ethical standards of the 
Helsinki Declaration (1964, amended most recently in 2008) of the World Medical Association. 
Any information, including illustrations, has been anonymized. The Marshall University 
Institutional Review Board (IRB) has approved this research under the protocol #326290. Ethics 
committees/ IRB at Marshall University approved this consent procedure.  
 
Three-Dimensional Bioreactor CSCs Culture  
A hydrodynamic focusing bioreactor (HFB) (Celdyne, Houston TX) was used as 
previously described to selectively proliferate the CD133 (+) cancer stem-like cells (45).  
 
Cell Sorting 
Up to 10 million cells were sorted for CD133+ cells by a magnetic-activated cell sorting 
(MACS) system as described before (50).  
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Flow Cytometry Studies 
Cells were analyzed by the antigenic criteria using anti-CD34 (Milteny Biotech, Auburn, 
CA), -CD38 (Milteny Biotech, Auburn, CA), -CD44 (BD Bioscience, Sparks, MD), -CD133/2 
(prominin1) (Milteny Biotech, Auburn, CA), -CXCR4 (BD Bioscience, Sparks, MD),  -Oct3/4 
(BD Bioscience, Sparks, MD), and –Nanog (BD Bioscience, Sparks, MD). All methods were 
performed as previously described (50). 
 
Chemotherapy Sensitivity Assay 
Sensitivity to chemotherapy was assessed using the viability assay MTT on 10,000 cells 
plated in four replicas into 96-well plates. Briefly, equal numbers of bulk tumor cells grown in a 
monolayer and CSLCs grown in the bioreactor, were counted and seeded separately in 96-well 
dishes and incubated at 37°C for 24 hours. The cells were then challenged with a one-hour pulse 
of a panel of individual anticancer drugs as chosen by the oncologist to mimic the average 
clinical chemotherapy infusion schedule.  
An MTT assay was performed 24 hours following chemotherapy treatment to assess cell 
viability. A dose response chart was developed in which samples were scored as responsive 
(100–60% cell death), intermediate (60–30% cell death), and non-responsive (0–30% cell death). 
 
Animal Study  
All animal studies were conducted following approval from the Marshall University 
IACUC, protocol #373017. The effects of chemotherapies screened in vitro by the chemotherapy 
sensitivity assay were tested on human tumor biopsies that were xenografted in the flank of a 
NOD-Scid mouse model. This was performed using a previously established method (50). 
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Animals were euthanized following the current guidelines established by the latest Report 




Statistical analysis was performed as previously established (50). P-values of less than 







Patient 1  
The patient is a 56-year-old male who had a craniotomy on April 18th 2012. The 
pathology report came back as Glioblastoma IDH-1 mutant. Appropriate informed consent was 
signed and at the time of the debulking surgery, a sterile biopsy was taken to assess the 
sensitivity of the tumor cells (bulk of tumor and CSLCs) toward standard-of-care chemotherapy 
drugs using a chemotherapy sensitivity assay. The biopsy was placed in collection/transport 
media and tissue was dissociated in the laboratory into a single-cell suspension with the use of a 
GentleMACS tissue dissociator (Miltenyi, Aubourn, CA). The single-cell GBM suspension was 
plated as previously reported (50) and cells were cultured as a monolayer for 15 days. Cells were 
immunophenotyped by flow cytometer using antibodies against CD133, CD34, CD38, CD44, 














Figure 14. Flow Cytometer Data for GBM Patient 1. 
FL1-A is the filter used to measure Fitc, FL2-A is the filter used to measure PE, FL4- A is used to 
measure APC. A) Negative control showing FSC and SSC on cells not labeled with any antibody. B) 
Isotype control for PE. C) Isotype control for Fitc. D) Isotype control for APC. E) CD133/2-PE labeled 
cells. F) Isotype control for Fitc vs APC. G) CD38-Fitc Antibody vs CD34-APC. Upper left quadrate is 
CD34+/CD38-, upper right quadrant is CD34+/CD38+, lower left quadrant is CD34-/CD38-, and lower 
right quadrant is CD34-/CD38+.  H) CXCR4-APC labeled cells. I) CD24-PE labeled cells. J) CD44-APC 
labeled cells. K) OCT 3/4-APC labeled cells. L) Nanog-Fitc labeled cells. 
  
Negative Isotype PE Isotype Fitc Isotype APC A B C D 
CD133 PE Isotype Fitc & APC CD34 APC & CD38 FITC CXCR4 APC E F G H 





 CD133 CD44 CD24 CXCR4 OCT3/4 Nanog CD34+/CD38- 
Percent 9.8 72.4 29.7 75.0 13.6 0.2 63.5 
 
Table 3. Flow Cytometer Data on GBM Patient 1. 
Shows the percent of cells tested that are positive for each biomarker compared to the Isotype controls. 
 
 
The GBM cells were found positive to CD133 (9.8%), CD44 (72.4%), CD 24 (29.7%), 
CXCR4 (75.0%), OCT3/4 (13.6%), and Nanog (0.2%) when compared to an isotype control 
antibody (Table 3). A double staining of CD34 and CD38 showed the presence of 1.6% of the 
cells CD34+/CD38+, and 63.5% CD34+/CD38- cells (Table 3). To expand the CSLC population 
of CD133+ cells from the GBM primary culture, the cells were cultured as previously described 
(50). 1x10 GBM cells were cultured in the HFB to isolate the CSLCs for chemotherapy 
sensitivity assay. When placed directly in non-attaching dish they maintained a cluster assembly 
(Figure 15A) and would repopulate the morphologically heterogeneous GBM culture after ten 
days in a regular tissue culture dish (Figure 15B). 
 
 
Figure 15. GBM Patient 1 Cells Cultured in Low Attachment Dish and Tissue Culture Treated Dish after 
being isolated for CD133 in HFB for seven days. 
A) GBM Patient 1 cells cultured in a low attachment dish after being isolated for CD133 using the HFB. 
Picture taken after three days in culture. B)  GBM Patient 1 cells cultured in a tissue culture treated dish 
after isolated for CD133 using the HFB. Picture taken after three days in culture. 
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   To perform the chemotherapy sensitivity assay, a comparable number (1x10⁵) of bulk of 
tumor cells grown, as a 2D monolayer, or isolated for CD133 using the HFB (50), were separately 
plated into 96 wells plates (n-4 replicas) and were treated for an hour with a series of anticancer 
drugs at a range of concentrations including the clinically relevant dosage (Table 4). 
Chemotherapy sensitivity assay was performed using a panel of drugs comprising of Temodar, 
Carboplatin, Cisplatin, Etoposide, Methotrexate, Arabinoside-C, Oxaliplatin, Irinotecan, and 
Bevacizumab. Sensitivity to chemotherapy was assessed at 24 hours by MTT viability assay. 
Results were categorized as follows based on the percentage of non-viable cells: responsive 
(100–60% cell kill), intermediate (30–60% cell kill), and non-responsive (0–30% cell kill). The 
MTT assay was conducted three separate times with n-4 well replicas/drug/dose each time 
(Figure 16). 
 















































Table 4. Clinical Dose and Calculated in vitro Doses of Chemotherapy for GBM Patients. 
 
Chemotherapy sensitivity assay showed that the bulk of tumor of Patient 1 cells grown in 
monolayer and were intermediately responsive to clinically relevant doses of Temodar (TMZ), 
Irinotecan (CPT-11) + Bevacizumab (Avastin) combination, Cisplatin (CDDP), Irinotecan (CPT-
11), Methotrexate (MTX), and Oxaliplatin (OXA). Interestingly, the CSLCs were only 
intermediately responsive to a combination of Irinotecan (CPT-11) and Bevacizumab (Avastin) 




Figure 16. Diagram of Chemotherapy Sensitivity Assay to Assess the Response to GBM Patient 1 cells 
and CSLCs Using MTT Assay. 
1x10³ bulk of tumor cells or CSLCs plated in four replicas into 96-well plates and allowed overnight to 
attach. Then cells were challenged with a one-hour pulse of varying chemotherapeutic agents. A MTT 
assay was performed 24 hours following chemotherapy treatments to assess cell viability. Data is plotted 
in bar graph as responsive (100–60% cell death), intermediately responsive (60–30% cell death), and non-
responsive (0–30% cell death). Light grey bars represent sensitivity of CSLCs to chemotherapy with 
respect to negative untreated control cells. The black bars represent sensitivity of bulk of tumor cells to 
chemotherapy with respect to negative untreated control cells. Anticancer drugs tested indicated at the 
bottom of the diagram. Statistical analysis of the significance of the results was performed with a one-way 
















































This patient was treated with surgery followed by standard-of-care first-line therapy of 
Temodar and radiation. At the six months follow-up this patient showed an initial response 
demonstrated by the diminished size of the tumor at the MRI, but was found to have a tumor 
relapse at the 12 months follow-up (Figure 17 A, B, & C). Unfortunately, as shown in the 
follow-up MRI scan at 18 months, the tumor had continued to progress causing the patient to 




     
     
Figure 17. MRI Images from GBM Patient 1. 
A. Preoperative MRI of the brain with left frontal lobe GBM crossing the midline into the left frontal lobe 
& invading the corpus callosum with large amount of associated edema & hydrocephalus. B. Post-
operative MRI six months post resection & radiation showing regression of the disease.  C. 12 months 
post therapy MRI showing progression of residual disease.  D.  18 months post therapy MRI showing 
progression of the disease back to bi-frontal mass with increased invasion of corpus callosum and mass 
affecting on the ventricular system with return of hydrocephalus. 
 
 





 Patient 2 is a 35-year-old male who had a craniotomy on June 11th 2012. Pathology 
report came back as Glioblastoma IDH-1 wild type. Appropriate informed consent was signed 
and at the time of the debulking surgery, a sterile biopsy was taken to assess the sensitivity of the 
tumor cells (bulk of tumor and CSLCs) toward standard-of-care chemotherapy drugs using our 
chemotherapy sensitivity assay. The biopsy was placed in collection/transport media and tissue 
was dissociated in the laboratory into a single-cell suspension with the use of a GentleMACS 
tissue disassociator (Miltenyi, Aubourn, CA). The single-cell GBM suspension was plated as 
previously reported (49) and cells were cultured as a monolayer for 15 days. Cells were 
immunophenotyped by flow cytometry using antibodies against CD133, CD34, CD38, CD44, 







Figure 18. Flow Cytometer Data for GBM Patient 2. 
FL1-A is the filter used to measure Fitc, FL2-A is the filter used to measure PE, FL4- A is used to 
measure APC. A) Negative control showing FSC and SSC on cells not labeled with any antibody. B) 
Isotype control for PE. C) Isotype control for Fitc. D) Isotype control for APC. E) CD133/2-PE labeled 
cells. F) Isotype control for Fitc vs APC. G) CD38-Fitc Antibody vs CD34-APC. Upper left quadrate is 
CD34+/CD38-, upper right quadrant is CD34+/CD38+, lower left quadrant is CD34-/CD38-, and lower 
right quadrant is CD34-/CD38+.  H) CD44-APC labeled cells. I) CD24-PE labeled cells. J) CXCR4-APC 
labeled cells. K) OCT 3/4-APC labeled cells. L) Nanog-Fitc labeled cells. 
  
Negative Isotype PE Isotype Fitc Isotype APC 
Isotype APC & Fitc CD34 APC & CD38 Fitc CD44 APC 
CD24 PE CXCR4 APC 
CD133 PE 
OCT4 APC Nanog Fitc 
B A C 
E 
D 
F H G 
K I L J 
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 CD133 CD44 CD24 CXCR4 OCT3/4 Nanog CD34+/CD38- 
Percent 12.3 11.9 16.6 43.6 25.1 4.9 13.1 
 
Table 6. Flow Cytometer Data on GBM Patient 2. 
Shows the percent of cells tested that are positive for each biomarker compared to the Isotype controls. 
 
 
The GBM cells were found positive to CD133 (12.3%), CD44 (11.9%), CD 24 (16.6%), 
CXCR4 (43.6%), OCT3/4 (25.1%), and Nanog (4.9%) when compared to an isotype control 
antibody (Table 6). A double staining of CD34 and CD38 showed the presence of 1.6% of the 
cells CD34+/CD38+, and 13.1% CD34+/CD38- cells (Table 6). To expand the CSLC population 
of CD133+ cells from the GBM primary culture, the cells were cultured as previously described 
(50). The GBM cells cultured and isolated for CD133 using the HFB for chemotherapy 
sensitivity assay. When placed directly in non-attaching dish they maintained a cluster assembly 
(Figure 19A) and would repopulate the heterogeneous GBM culture after ten days in a regular 
tissue culture dish (Figure 19B). 
 
 
Figure 19. GBM Patient 2 Cells Cultured in Low Attachment Dish and Tissue Culture Treated Dish after 
being isolated for CD133 using the HFB. 
A) GBM Patient 2 cells cultured in a low attachment dish after being isolated for CD133 using the HFB. 
Picture taken after three days in culture. B)  GBM Patient 2 cells cultured in a tissue culture treated dish 
after being isolated for CD133 using the HFB. Picture taken after three days in culture. 
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To perform the chemotherapy sensitivity assay 1x10⁵cells	of	either bulk of tumor cells 
grown as a 2D monolayer or isolated for CD133 using the HFB (50) were separately plated into 
96 wells plates (n-4 replicas) and were treated for an hour with a series of anticancer drugs at a 
range of concentrations including the clinically relevant dosage as done for GBM Patient 1 
(Table 4).  Again, chemotherapy sensitivity assay was performed using a panel of drugs 
comprising of Temodar, Carboplatin, Cisplatin, Etoposide, Methotrexate, Arabinoside-C, 
Oxaliplatin, Irinotecan, and Bevacizumab. Sensitivity to chemotherapy was assessed at 24 hours 
by MTT viability assay. Results were categorized as follows based on the percentage of non-
viable cells: responsive (100–60% cell kill), intermediate (30–60% cell kill), and non-responsive 
(0–30% cell kill). The MTT assay was conducted three separate times with n-4 well 
replicas/drug/dose each time (Figure 20). 
This patient was treated with surgery followed by standard-of-care first line 
chemotherapy with Temodar and radiation therapy.  Notably, at the six month post treatment 
follow-up, the patient showed a positive response with tumor regression as demonstrated by an 
MRI scan (Figure 21 A, B, & C).  A follow-up MRI scan at 18 months showed no evidence of 





Figure 20.  Diagram of Chemotherapy Sensitivity Assay to Assess the Response to GBM Patient 2 cells 
and CSLCs Using MTT Assay. 
1x10³ bulk of tumor cells or CSLCs plated in four replicas into 96-well plates and allowed overnight to 
attach. Then cells were challenged with a one-hour pulse of varying chemotherapeutic agents. A MTT 
assay was performed 24 hours following chemotherapy treatments to assess cell viability. Data is plotted 
in bar graph as responsive (100–60% cell death), intermediately responsive (60–30% cell death), and non-
responsive (0–30% cell death). Light grey bars represent sensitivity of CSLCs to chemotherapy with 
respect to negative untreated control cells. The black bars represent sensitivity of bulk of tumor cells to 
chemotherapy with respect to negative untreated control cells. Anticancer drugs tested indicated at the 
bottom of the diagram. Statistical analysis of the significance of the results was performed with a 1-way 



















































Figure 21. MRI Images from GBM Patient 2. 
A. Pre-operative MRI of the brain showing a rim-enhancing GBM in the left cerebrum with edema 
causing mass effect on the ventricles and ballooning of the left temporal horn & mass effect on the basal 
cistern.  B. Post-surgical resection MRI shows linear non-nodular enhancement likely related to surgery.  
C. Six months post therapy MRI without evidence of tumor recurrence.  D. 18 months post therapy 
without evidence of tumor recurrence or progression at the operative bed or distantly. 
 
 




The efficacy of chemotherapies screened in vitro by the chemotherapy sensitivity assay 
was tested on the GBM cells of Patient 1 and Patient 2 that were xenografted in a NOD-Scid 
mouse model (Figure 22 & 23). Ten athymic NOD-Scid mice were injected in the flank with 
1x10 GBM cells mixed to 100 µL of matrigel (BD Biosciences, San Jose, CA) and tumors were 
grown for ten weeks or until 100 mm³. Randomized mice were treated by weekly intraperitoneal 
(i.p.) injections of the different treatments for four weeks and were observed for four more 
weeks. Group #1 serving as a control received i.p. sterile saline injections. Groups #2–6 were the 
experimental groups, which received i.p. injections of the least effective chemotherapy, or the 
most effective, the second most effective, and the most effective combinatorial chemotherapy, as 
determined by the in vitro chemotherapy sensitivity assay. 
The tumor xenografts in the Scid mice injected with the least effective chemotherapy as 
determined by the in vitro chemotherapy sensitivity assay grew faster than any other treatment 
other than the saline control injected mice (Figure 22 Top 23 Top).  
Interestingly, tumor regression was initially seen in Scid mice injected with cells from 
GBM Patient 1 treated TMZ, but after treatment was stopped, at week six, tumor began to grow 
again (Figure 22 Top). This was confirmed with clinical patient data (Figure 17) that showed 
after treatment of TMZ and radiation the patient relapsed. The best response by cells from GBM 
Patient 1 was to combinatorial chemotherapy of CPT-11 + Avastin as determined by the in vitro 





Figure 22. Mean Tumor Volume and Mean Tumor Weight of GBM Patient 1 Derived Xenografts Treated 
with i.p. Injection of Anticancer Drugs. 
Top) Line diagram of the mean volumes in mm³ (±SD) from week 2–8 of ten GBM Patient 1 derived 
xenografted tumors in NOD-Scid mice following four weeks of treatment with various anticancer drugs. 
The mean tumor volumes are indicated on the ordinate. Asterisks indicate weeks in which treatment was 
performed. On the right are indicated the different treatment arms. PBS: saline solution, negative control. 
Temodar; MTX (Methotrexate), CPT-11 (Irinotecan); Avastin (Bevacizumab); CPT-11 (Irinotecan) + 
Avastin (Bevacizumab). Bottom) Line diagram of the mean weight in grams (±SD) of ten NOD-Scid 
mice-bearing patient derived xenografted tumors following four weeks of treatment with various 
anticancer drugs. The mean tumor weights are indicated on the ordinate. Asterisks indicate weeks in 
which treatment was performed. On the right are indicated the different treatment arms. PBS: saline 
solution, negative control. Temodar; MTX (Methotrexate), CPT-11 (Irinotecan); Avastin (Bevacizumab); 
CPT-11 (Irinotecan) + Avastin (Bevacizumab).  
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Tumor regression was reported in Scid mice injected with GBM cells from Patient 2, 
which were treated with the most effective chemotherapy (TMZ) that was confirmed to be the 
most effective treatment in the in vitro chemosensitivity test (Figure 23 Top). This was 
confirmed by the clinical patient data (Figure 21) that showed after treatment of TMZ and 
radiation the patient was in remission. The second best response of GBM Patient 2 was to 
combinatorial chemotherapy of CPT-11 + Avastin as predicted by the in vitro chemotherapy 
sensitivity assay and as determined by the xenograft treatment. Mice weights were measured 





Figure 23. Mean Tumor Volume and Mean Tumor Weight of GBM Patient 2 Derived Xenografts Treated 
with i.p. Injection of Anticancer Drugs. 
Top) Line diagram of the mean volumes in mm³ (±SD) from week 2–8 of ten GBM Patient 2 derived 
xenografted tumors in NOD-Scid mice following four weeks of treatment with various anticancer drugs. 
The mean tumor volumes are indicated on the ordinate. Asterisks indicate weeks in which treatment was 
performed. On the right are indicated the different treatment arms. PBS: saline solution, negative control. 
Temodar; MTX (Methotrexate), CPT-11 (Irinotecan); Avastin (Bevacizumab); CPT-11 (Irinotecan) + 
Avastin (Bevacizumab). Bottom) Line diagram of the mean weight in grams (±SD) of ten NOD-Scid 
mice-bearing patient derived xenografted tumors following four weeks of treatment with various 
anticancer drugs. The mean tumor weights are indicated on the ordinate. Asterisks indicate weeks in 
which treatment was performed. On the right are indicated the different treatment arms. PBS: saline 
solution, negative control. Temodar; MTX (Methotrexate), CPT-11 (Irinotecan); Avastin (Bevacizumab); 







Treatment for Glioblastoma (GBM) is often a combinatorial approach that includes 
surgery, radiation therapy, and chemotherapy. Temozolomide (TMZ) is the primary 
chemotherapeutic agent used in the treatment of GBM but is often non-curative and patients 
frequently experience tumor relapse due to chemoresistance.   
As shown in this study of two GBM cases the different responses to chemotherapy 
determined by the chemosensitivity assay on the CSLCs resulted in a distinct and opposite 
outcome for the patient.   
To advance our ability to more thoroughly understand the CSLC driving force within 
heterogeneous tumors such as GBMs, a procedure that can successfully enrich the CSLC 
population from tumor biopsy specimens was developed. These enriched CSLCs are then used to 
assess their intrinsic resistance or sensitivity to chemotherapy vs. the resistance of primary 
cultures derived from the total heterogeneous tumor. This method successfully facilitated the 
enrichment of CD133+ CSLCs from fresh GBM biopsy tissues allowing the selective evaluation 
of chemotherapy response of the CSLC population compared to the response of the parenteral 
heterogeneous tumor cell population. Results using this procedure showed that GBM tumors do 
contain populations of CSLCs that can be selectively enriched, and that the chemoresistance or 
sensitivity status of CSLCs to TMZ predicted the patients’ treatment outcome in GBM patients 
receiving the standard-of-care Temozolomide (TMZ) regimen.   
GBM Patient 1 was diagnosed with a GBM IDH-1 mutant, which should have 
experienced a better outcome following treatment with TMZ. However, following standard 
chemoradiation treatment a recurrence was observed within six months. GBM patient 2, who 
was diagnosed with a GMB, but IDH-1 wild type, should have had worse prognosis following 
standard chemoradiation treatment. Instead patient 2 showed a positive response with tumor 
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regression as demonstrated by MRI scans indicating that genetic analysis, of a single marker, to 
predict tumor response may not be an accurate method of patient stratification. 
This study accurately predicted that Patient 1 would relapse because the CSLCs would 
not be affected by the TMZ treatment, thereby causing the CSLCs to reinitiate the tumor. In 
contrast, Patient 2 was predicted to respond well to the treatment received by the chemotherapy 
sensitivity assay. Figure 24 shows the responses of GBM Patient 1 and 2 to TMZ using the 





Figure 24. Diagram of GBM Patient 1 and Patient 2 Response to TMZ using the Chemotherapy 
Sensitivity Assay on both the Bulk of the tumor and the CSLCs. 
 
This outcome was also challenged using NOD-Scid mice xenografts treated with the most 
effective, the second most effective, and the most effective combinatorial chemotherapy as 
determined by the in vitro chemotherapy sensitivity assay. As expected, results from tumor 
xenografts generated by injecting enriched GBM CSLCs from the two patients in the flank of 
NOD-Scid mice, followed by treatment with select chemotherapies, were also found to be in 
agreement with the clinical outcomes for the patients’ response to TMZ at follow-up. Regression 
was observed at first in tumor xenografts from Patient 1 cells treated with TMZ; however, 
following cessation of the TMZ treatment relapse was observed (Figure 22). Interestingly, 
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xenografts from Patient 2 treated with TMZ, responded well to the treatment and a regression of 
the tumors was observed (Figure 23).    
This data shows the importance of determining the sensitivity of CSLCs to chemotherapy 
and their role in predicting patient tumor response following chemotherapy. This data further 
supports our belief that long-term tumor response in GBM is in fact more dependent on the 
intrinsic sensitivity or resistance of the CSLC population than the general tumor cell population 
and needs to be closely studied to determine how this population can be targeted for therapy.  
This method will provide critical information about an individual patient’s possibility to achieve 
a complete tumor response status before implementing the patient’s treatment plan. Although the 
chemotherapy sensitivity assay results of these two cases of GBM showed to be clinically 
relevant, this laboratory is currently conducting a larger study on a series of GBMs to determine 




CHAPTER 4: CONCLUSIONS AND FUTURE DIRECTIONS 
 
 Chapter 1 reviewed the current literature on CNS cancer treatments, cancer stem cell 
theory, and standard-of-care anticancer drugs. In this chapter the potential for chemotherapy 
sensitivity assay on cancer stem-like cells to establish personalized patient therapy was 
highlighted. The method of how this assay is performed and its validation is also outlined in this 
chapter.  
Chapter 2 discussed the relevance and outcome of two patients affected by Ependymoma.  
The ependymoma of Patient 1 was found sensitive to a combination of Irinotecan + Avastin, but 
resistant to Oxaliplatin. This data was confirmed by an animal study in which mice treated with 
Oxaliplatin and failing therapy could be rescued with a combination of Irinotecan + Avastin.  
This study also showed that an adjuvant supplementation of BITC extracted from broccoli 
sensitized CSLCs to chemotherapy and increased its efficacy both in vitro and in vivo. 
Unfortunately, the ependymoma of patient 2 was found not responding to the chemotherapies 
used and was also resistant to the same anticancer drugs when tested in the in vitro 
chemosensitivity assay. 
 In Chapter 3, the chemotherapy sensitivity assay was investigated in two glioblastoma 
cases. The CSLCs of GBM Patient 1 were found resistant to TMZ by the chemotherapy 
sensitivity assay. Following a regimen of chemoradiation with TMZ this patient relapsed after a 
year. The clinical outcome of patient 1 was found in accordance with both the in vivo and in vitro 
studies performed in the laboratory. GBM Patient 2 was also treated with chemoradiation with 
TMZ, but interestingly this patient showed a completely different clinical outcome being free 
from progression for 18 months. In patient 2, the chemotherapy sensitivity assay accurately 
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predicted that both bulk of the tumor cells and CSLCs would respond to TMZ, which was also 
confirmed by a study conducted using mice xenografts.  
The chemotherapy sensitivity assay has shown great promise in these four cases. This 
assay demonstrated that the CSLC population must be assayed to better predict patient outcomes 
because of the known resistance of CSLCs to anticancer drugs. By combining the information 
gathered for both Bulk and CSLC population, new treatment modalities could be established that 
could lead to increased survival rates.  
In addition, the clinical study presented above suggests that future studies of natural 
compounds such as BITC and others should be performed to further increase our understanding 
of the potential of botanical extracts and compounds as adjuvant to chemotherapy.  
One of the shortcomings of the present study is that O 6-methylguanine DNA 
methyltransferase (MGMT) status was not investigated on the samples. MGMT gene encodes for 
a protein that is involved in DNA repair by removing the alkyl groups (108). This is problematic 
for proscribed chemotherapeutic drugs, like TMZ, that are alkylating agents that place alkyl 
groups on the DNA so that replication cannot occur (108). MGMT activity is regulated by 
epigenetic factors that methylate the promoter region of the gene to reduce the amount of 
MGMT in a GBM cell (108). MGMT gene methylation has been shown to be associated with 
improved outcome in GBM and may be a predictive marker of sensitivity to alkylating agents. 
While MGMT status of these tissues has not been examined, it is an experiment to consider for 
the future. 
Another shortcoming of the present studies is the lack of large clinical data; however, the 
clinical data from a series of twenty-five GBMs is currently being evaluated. In conclusion, this 
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present body of work supports the knowledge that chemotherapy sensitivity assays on CSLCs are 
a promising tool to more accurately predict patient outcome following anticancer treatment. This 
assay has the potential to be standardized and used in clinical settings, being novel in its 
approach to analyze the sensitivity/resistance of CSLCs to anticancer drugs and hopefully 







I would like to again thank all the doctors involved in this clinical study. Dr. Anthony 
Alberico, Dr. Robert A. Marsh, Dr. Terrence D. Julien, Dr. Ahmad Mazagri, Dr. Aneel 
Chowdhary, Dr. Arvinder Bir, Dr. Candace Howard, Dr. Gerard Oakley, III, Dr. Gerrit A. 
Kimmey, Dr. Linda Brown, Dr. Michael Bloom, and Dr. Thomas Dougherty.  
I would like to give a special thank you to my advisor Dr. Pier Paolo Claudio for all the 












We gratefully acknowledge the Marshall University Biochemistry and Microbiology & 
Surgery Departments for their support. The present studies were supported by the CDDC, NCI-
NIH-CTSA MU/UK, MU Neuroscience internal funds, MU Translational Research Award, and 
NASA. The funders had no role in study design, data collection and analysis, decision to publish, 
or preparation of manuscripts. The content is solely the responsibility of the authors and does not 





1. Carpinelli, G., Bucci, B., D'Agnano, I., Canese, R., Caroli, F., Raus, L., Brunetti, E., Giannarelli, 
D., Podo, F., and Carapella, C. M. (2006) Gemcitabine treatment of experimental C6 glioma: the 
effects on cell cycle and apoptotic rate. Anticancer research 26, 3017-3024 
2. Arienti, C., Tesei, A., Verdecchia, G. M., Framarini, M., Virzi, S., Grassi, A., Scarpi, E., Turci, 
L., Silvestrini, R., Amadori, D., and Zoli, W. (2011) Peritoneal carcinomatosis from ovarian 
cancer: chemosensitivity test and tissue markers as predictors of response to chemotherapy. 
Journal of translational medicine 9, 94 
3. Triscott, J., Pambid, M. R., and Dunn, S. E. (2015) Bullseye: Targeting cancer stem cells to 
improve the treatment of gliomas by repurposing Disulfiram. Stem cells  
4. Roda, E., Nion, S., Bernocchi, G., and Coccini, T. (2014) Blood-brain barrier (BBB) toxicity and 
permeability assessment after L-(4-(1)(0)Boronophenyl)alanine, a conventional B-containing 
drug for boron neutron capture therapy, using an in vitro BBB model. Brain research 1583, 34-44 
5. Castelo-Branco, P., and Tabori, U. (2012) Promises and challenges of exhausting pediatric neural 
cancer stem cells. Pediatric research 71, 523-528 
6. Gong, X., Schwartz, P. H., Linskey, M. E., and Bota, D. A. (2011) Neural stem/progenitors and 
glioma stem-like cells have differential sensitivity to chemotherapy. Neurology 76, 1126-1134 
7. Nasser, S., Kurdolgu, A. A., Izatt, T., Aldrich, J., Russell, M. L., Christoforides, A., Tembe, W., 
Keifer, J. A., Corneveaux, J. J., Byron, S. A., Forman, K. M., Zuccaro, C., Keats, J. J., Lorusso, 
P. M., Carpten, J. D., Trent, J. M., and Craig, D. W. (2015) An integrated framework for 
reporting clinically relevant biomarkers from paired tumor/normal genomic and transcriptomic 
sequencing data in support of clinical trials in personalized medicine. Pacific Symposium on 
Biocomputing. Pacific Symposium on Biocomputing, 56-67 
8. Devon, K. M., Lerner-Ellis, J. P., Ganai, S., and Angelos, P. (2015) Ethics and genomic 
medicine, how to navigate decisions in surgical oncology. Journal of surgical oncology 111, 18-
23 
9. Herzog, T. J., Krivak, T. C., Fader, A. N., and Coleman, R. L. (2010) Chemosensitivity testing 
with ChemoFx and overall survival in primary ovarian cancer. American journal of obstetrics and 
gynecology 203, 68 e61-66 
10. Suchy, S. L., Hancher, L. M., Wang, D., Ervin, P. R., Jr., and Brower, S. L. (2011) 
Chemoresponse assay for evaluating response to sunitinib in primary cultures of breast cancer. 
Cancer biology & therapy 11, 1059-1064 
11. Rice, S. D., Heinzman, J. M., Brower, S. L., Ervin, P. R., Song, N., Shen, K., and Wang, D. 
(2010) Analysis of chemotherapeutic response heterogeneity and drug clustering based on 
mechanism of action using an in vitro assay. Anticancer research 30, 2805-2811 
12. Rice, S. D., Cassino, T. R., Sakhamuri, L., Song, N., Williams, K. E., and Brower, S. L. (2011) 
An in vitro chemoresponse assay defines a subset of colorectal and lung carcinomas responsive to 
cetuximab. Cancer biology & therapy 11, 196-203 
94 
 
13. Fangusaro, J. (2012) Pediatric high grade glioma: a review and update on tumor clinical 
characteristics and biology. Frontiers in oncology 2, 105 
14. Louis, D. N., Ohgaki, H., Wiestler, O. D., Cavenee, W. K., Burger, P. C., Jouvet, A., Scheithauer, 
B. W., and Kleihues, P. (2007) The 2007 WHO classification of tumours of the central nervous 
system. Acta neuropathologica 114, 97-109 
15. Mikita, T., and Beardsley, G. P. (1994) Effects of arabinosylcytosine-substituted DNA on 
DNA/RNA hybrid stability and transcription by T7 RNA polymerase. Biochemistry 33, 9195-
9208 
16. Los, M., Roodhart, J. M., and Voest, E. E. (2007) Target practice: lessons from phase III trials 
with bevacizumab and vatalanib in the treatment of advanced colorectal cancer. The oncologist 
12, 443-450 
17. Spitzer, M. S., Yoeruek, E., Sierra, A., Wallenfels-Thilo, B., Schraermeyer, U., Spitzer, B., Bartz-
Schmidt, K. U., and Szurman, P. (2007) Comparative antiproliferative and cytotoxic profile of 
bevacizumab (Avastin), pegaptanib (Macugen) and ranibizumab (Lucentis) on different ocular 
cells. Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes 
Archiv fur klinische und experimentelle Ophthalmologie 245, 1837-1842 
18. Bogusz, J., Majchrzak, A., Medra, A., Cebula-Obrzut, B., Robak, T., and Smolewski, P. (2013) 
Mechanisms of action of the anti-VEGF monoclonal antibody bevacizumab on chronic 
lymphocytic leukemia cells. Postepy higieny i medycyny doswiadczalnej 67, 107-118 
19. Ellis, L. M. (2006) Mechanisms of action of bevacizumab as a component of therapy for 
metastatic colorectal cancer. Seminars in oncology 33, S1-7 
20. Iwamoto, T., Hiraku, Y., Oikawa, S., Mizutani, H., Kojima, M., and Kawanishi, S. (2004) DNA 
intrastrand cross-link at the 5'-GA-3' sequence formed by busulfan and its role in the cytotoxic 
effect. Cancer science 95, 454-458 
21. Knox, R. J., Friedlos, F., Lydall, D. A., and Roberts, J. J. (1986) Mechanism of cytotoxicity of 
anticancer platinum drugs: evidence that cis-diamminedichloroplatinum(II) and cis-diammine-
(1,1-cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with 
DNA. Cancer research 46, 1972-1979 
22. Natarajan, G., Malathi, R., and Holler, E. (1999) Increased DNA-binding activity of cis-1,1-
cyclobutanedicarboxylatodiammineplatinum(II) (carboplatin) in the presence of nucleophiles and 
human breast cancer MCF-7 cell cytoplasmic extracts: activation theory revisited. Biochemical 
pharmacology 58, 1625-1629 
23. Wheate, N. J., Walker, S., Craig, G. E., and Oun, R. (2010) The status of platinum anticancer 
drugs in the clinic and in clinical trials. Dalton transactions 39, 8113-8127 
24. Hongo, A., Seki, S., Akiyama, K., and Kudo, T. (1994) A comparison of in vitro platinum-DNA 
adduct formation between carboplatin and cisplatin. The International journal of biochemistry 26, 
1009-1016 
25. Ren, S., and Slatterly, J. T. (1999) Inhibition of carboxyethylphosphoramide mustard formation 
from 4-hydroxycyclophosphamide by carmustine. AAPS pharmSci 1, E14 
95 
 
26. Rixe, O., Ortuzar, W., Alvarez, M., Parker, R., Reed, E., Paull, K., and Fojo, T. (1996) 
Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines 
and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel. Biochemical 
pharmacology 52, 1855-1865 
27. Bromberg, K. D., Burgin, A. B., and Osheroff, N. (2003) A two-drug model for etoposide action 
against human topoisomerase IIalpha. The Journal of biological chemistry 278, 7406-7412 
28. Buckner, J. C., Reid, J. M., Wright, K., Kaufmann, S. H., Erlichman, C., Ames, M., Cha, S., 
O'Fallon, J. R., Schaaf, L. J., and Miller, L. L. (2003) Irinotecan in the treatment of glioma 
patients: current and future studies of the North Central Cancer Treatment Group. Cancer 97, 
2352-2358 
29. Vredenburgh, J. J., Desjardins, A., Reardon, D. A., and Friedman, H. S. (2009) Experience with 
irinotecan for the treatment of malignant glioma. Neuro-oncology 11, 80-91 
30. Shinwari, Z., Manogaran, P. S., Alrokayan, S. A., Al-Hussein, K. A., and Aboussekhra, A. (2008) 
Vincristine and lomustine induce apoptosis and p21(WAF1) up-regulation in medulloblastoma 
and normal human epithelial and fibroblast cells. Journal of neuro-oncology 87, 123-132 
31. Bartzatt, R. (2013) Lomustine analogous drug structures for intervention of brain and spinal cord 
tumors: the benefit of in silico substructure search and analysis. Chemotherapy research and 
practice 2013, 360624 
32. Rajagopalan, P. T., Zhang, Z., McCourt, L., Dwyer, M., Benkovic, S. J., and Hammes, G. G. 
(2002) Interaction of dihydrofolate reductase with methotrexate: ensemble and single-molecule 
kinetics. Proceedings of the National Academy of Sciences of the United States of America 99, 
13481-13486 
33. Goerne, R., Bogdahn, U., and Hau, P. (2008) Procarbazine--a traditional drug in the treatment of 
malignant gliomas. Current medicinal chemistry 15, 1376-1387 
34. Pletsa, V., Valavanis, C., van Delft, J. H., Steenwinkel, M. J., and Kyrtopoulos, S. A. (1997) 
DNA damage and mutagenesis induced by procarbazine in lambda lacZ transgenic mice: 
evidence that bone marrow mutations do not arise primarily through miscoding by O6-
methylguanine. Carcinogenesis 18, 2191-2196 
35. van den Bent, M. J., Chinot, O., Boogerd, W., Bravo Marques, J., Taphoorn, M. J., Kros, J. M., 
van der Rijt, C. C., Vecht, C. J., De Beule, N., and Baron, B. (2003) Second-line chemotherapy 
with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and 
vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972. Annals of 
oncology : official journal of the European Society for Medical Oncology / ESMO 14, 599-602 
36. Whitelaw, D. M., and Kim, H. S. (1964) Vincristine in the Treatment of Neoplastic Disease. 
Canadian Medical Association journal 90, 1385-1389 
37. LaPointe, N. E., Morfini, G., Brady, S. T., Feinstein, S. C., Wilson, L., and Jordan, M. A. (2013) 
Effects of eribulin, vincristine, paclitaxel and ixabepilone on fast axonal transport and kinesin-1 
driven microtubule gliding: implications for chemotherapy-induced peripheral neuropathy. 
Neurotoxicology 37, 231-239 
96 
 
38. Sengupta, A., and Cancelas, J. A. (2010) Cancer stem cells: a stride towards cancer cure? Journal 
of cellular physiology 225, 7-14 
39. Pacini, N., and Borziani, F. (2014) Cancer stem cell theory and the warburg effect, two sides of 
the same coin? International journal of molecular sciences 15, 8893-8930 
40. Duan, J. J., Qiu, W., Xu, S. L., Wang, B., Ye, X. Z., Ping, Y. F., Zhang, X., Bian, X. W., and Yu, 
S. C. (2013) Strategies for isolating and enriching cancer stem cells: well begun is half done. 
Stem cells and development 22, 2221-2239 
41. Carlsson, S. K., Brothers, S. P., and Wahlestedt, C. (2014) Emerging treatment strategies for 
glioblastoma multiforme. EMBO molecular medicine 6, 1359-1370 
42. Dick, J. (2013) Q&A: John Dick on stem cells and cancer. Cancer discovery 3, 131 
43. Bu, Y., and Cao, D. (2012) The origin of cancer stem cells. Front Biosci (Schol Ed) 4, 819-830 
44. Dick, J. E. (2008) Stem cell concepts renew cancer research. Blood 112, 4793-4807 
45. Kelly, S. E., Di Benedetto, A., Greco, A., Howard, C. M., Sollars, V. E., Primerano, D. A., 
Valluri, J. V., and Claudio, P. P. (2010) Rapid selection and proliferation of CD133+ cells from 
cancer cell lines: chemotherapeutic implications. PloS one 5, e10035 
46. Brescia, P., Ortensi, B., Fornasari, L., Levi, D., Broggi, G., and Pelicci, G. (2013) CD133 is 
essential for glioblastoma stem cell maintenance. Stem cells 31, 857-869 
47. Peyre, M., Commo, F., Dantas-Barbosa, C., Andreiuolo, F., Puget, S., Lacroix, L., Drusch, F., 
Scott, V., Varlet, P., Mauguen, A., Dessen, P., Lazar, V., Vassal, G., and Grill, J. (2010) Portrait 
of ependymoma recurrence in children: biomarkers of tumor progression identified by dual-color 
microarray-based gene expression analysis. PloS one 5, e12932 
48. Singh, S. K., Hawkins, C., Clarke, I. D., Squire, J. A., Bayani, J., Hide, T., Henkelman, R. M., 
Cusimano, M. D., and Dirks, P. B. (2004) Identification of human brain tumour initiating cells. 
Nature 432, 396-401 
49. Tang, H., Gong, Y., Mao, Y., Xie, Q., Zheng, M., Wang, D., Zhu, H., Wang, X., Chen, H., Chen, 
X., and Zhou, L. (2012) CD133-Positive Cells Might Be Responsible for Efficient Proliferation 
of Human Meningioma Cells. International journal of molecular sciences 13, 6424-6439 
50. Mathis, S. E., Alberico, A., Nande, R., Neto, W., Lawrence, L., McCallister, D. R., Denvir, J., 
Kimmey, G. A., Mogul, M., Oakley, G., 3rd, Denning, K. L., Dougherty, T., Valluri, J. V., and 
Claudio, P. P. (2014) Chemo-predictive assay for targeting cancer stem-like cells in patients 
affected by brain tumors. PloS one 9, e105710 
51. Mimeault, M., and Batra, S. K. (2008) Targeting of cancer stem/progenitor cells plus stem cell-
based therapies: the ultimate hope for treating and curing aggressive and recurrent cancers. 
Panminerva medica 50, 3-18 
52. Pointer, K. B., Clark, P. A., Zorniak, M., Alrfaei, B. M., and Kuo, J. S. (2014) Glioblastoma 
cancer stem cells: Biomarker and therapeutic advances. Neurochemistry international 71, 1-7 
97 
 
53. La Porta, C. A. (2012) Thoughts about cancer stem cells in solid tumors. World journal of stem 
cells 4, 17-20 
54. Miyoshi, N., Ishii, H., Sekimoto, M., Haraguchi, N., Doki, Y., and Mori, M. (2010) Properties 
and identification of cancer stem cells: a changing insight into intractable cancer. Surgery today 
40, 608-613 
55. Nicolaidis, S. (2015) Biomarkers of glioblastoma multiforme. Metabolism: clinical and 
experimental 64, S22-27 
56. Stockert, J. C., Blazquez-Castro, A., Canete, M., Horobin, R. W., and Villanueva, A. (2012) MTT 
assay for cell viability: Intracellular localization of the formazan product is in lipid droplets. Acta 
histochemica 114, 785-796 
57. Ulukaya, E., Ozdikicioglu, F., Oral, A. Y., and Demirci, M. (2008) The MTT assay yields a 
relatively lower result of growth inhibition than the ATP assay depending on the 
chemotherapeutic drugs tested. Toxicology in vitro : an international journal published in 
association with BIBRA 22, 232-239 
58. Tominaga, H., Ishiyama, M., Ohseto, F., Sasamoto, K., Hamamoto, T., Suzuki, K., and 
Watanabe, M. (1999) A water-soluble tetrazolium salt useful for colorimetric cell viability assay. 
Analytical Communications 36, 47-50 
59. Hanbali, F., Fourney, D. R., Marmor, E., Suki, D., Rhines, L. D., Weinberg, J. S., McCutcheon, I. 
E., Suk, I., and Gokaslan, Z. L. (2002) Spinal cord ependymoma: radical surgical resection and 
outcome. Neurosurgery 51, 1162-1172; discussion 1172-1164 
60. Foreman, N. K., Laitt, R. D., Chambers, E. J., Duncan, A. W., and Cummins, B. H. (1995) 
Intracranial large vessel vasculopathy and anaplastic meningioma 19 years after cranial 
irradiation for acute lymphoblastic leukaemia. Medical and pediatric oncology 24, 265-268 
61. Cooper, I. S., Craig, W. M., and Kernohan, J. W. (1951) Tumors of the spinal cord; primary 
extramedullary gliomas. Surgery, gynecology & obstetrics 92, 183-190 
62. Bouffet, E., and Foreman, N. (1999) Chemotherapy for intracranial ependymomas. Child's 
nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery 
15, 563-570 
63. Chou, P. M., Barquin, N., Gonzalez-Crussi, F., Ridaura Sanz, C., Tomita, T., and Reyes-Mugica, 
M. (1996) Ependymomas in children express the multidrug resistance gene: 
immunohistochemical and molecular biologic study. Pediatric pathology & laboratory medicine : 
journal of the Society for Pediatric Pathology, affiliated with the International Paediatric 
Pathology Association 16, 551-561 
64. O'Brien, C. A., Kreso, A., and Jamieson, C. H. (2010) Cancer stem cells and self-renewal. 
Clinical cancer research : an official journal of the American Association for Cancer Research 
16, 3113-3120 
65. Aimola, P., Desiderio, V., Graziano, A., and Claudio, P. P. (2010) Stem cells in cancer therapy: 




66. Malik, B., and Nie, D. (2012) Cancer stem cells and resistance to chemo and radio therapy. 
Frontiers in bioscience 4, 2142-2149 
67. Yu, Y., Ramena, G., and Elble, R. C. (2012) The role of cancer stem cells in relapse of solid 
tumors. Frontiers in bioscience 4, 1528-1541 
68. Modena, P., Buttarelli, F. R., Miceli, R., Piccinin, E., Baldi, C., Antonelli, M., Morra, I., Lauriola, 
L., Di Rocco, C., Garre, M. L., Sardi, I., Genitori, L., Maestro, R., Gandola, L., Facchinetti, F., 
Collini, P., Sozzi, G., Giangaspero, F., and Massimino, M. (2012) Predictors of outcome in an 
AIEOP series of childhood ependymomas: a multifactorial analysis. Neuro-oncology 14, 1346-
1356 
69. van Meerloo, J., Kaspers, G. J., and Cloos, J. (2011) Cell sensitivity assays: the MTT assay. 
Methods in molecular biology 731, 237-245 
70. Reagan-Shaw, S., Nihal, M., and Ahmad, N. (2008) Dose translation from animal to human 
studies revisited. FASEB journal : official publication of the Federation of American Societies for 
Experimental Biology 22, 659-661 
71. Di Pasqua, A. J., Hong, C., Wu, M. Y., McCracken, E., Wang, X., Mi, L., and Chung, F. L. 
(2010) Sensitization of non-small cell lung cancer cells to cisplatin by naturally occurring 
isothiocyanates. Chemical research in toxicology 23, 1307-1309 
72. Wu, X., Zhou, Q. H., and Xu, K. (2009) Are isothiocyanates potential anti-cancer drugs? Acta 
pharmacologica Sinica 30, 501-512 
73. Merchant, T. E. (2002) Current management of childhood ependymoma. Oncology 16, 629-642, 
644; discussion 645-626, 648 
74. Chamberlain, M. C., and Tredway, T. L. (2011) Adult primary intradural spinal cord tumors: a 
review. Current neurology and neuroscience reports 11, 320-328 
75. Duffau, H., Gazzaz, M., Kujas, M., and Fohanno, D. (2000) Primary intradural extramedullary 
ependymoma: case report and review of the literature. Spine 25, 1993-1995 
76. McCormick, P. C., Post, K. D., and Stein, B. M. (1990) Intradural extramedullary tumors in 
adults. Neurosurgery clinics of North America 1, 591-608 
77. Pejavar, S., Polley, M. Y., Rosenberg-Wohl, S., Chennupati, S., Prados, M. D., Berger, M. S., 
Banerjee, A., Gupta, N., and Haas-Kogan, D. (2012) Pediatric intracranial ependymoma: the roles 
of surgery, radiation and chemotherapy. Journal of neuro-oncology 106, 367-375 
78. Song, K. W., Shin, S. I., Lee, J. Y., Kim, G. L., Hyun, Y. S., and Park, D. Y. (2009) Surgical 
results of intradural extramedullary tumors. Clinics in orthopedic surgery 1, 74-80 
79. Vandertop, W. P. (2003) Spinal cord ependymoma: radical surgical resection and outcome. 
Neurosurgery 53, 246; author reply 246-247 
80. Kocak, Z., Garipagaoglu, M., Adli, M., Uzal, M. C., and Kurtman, C. (2004) Spinal cord 
ependymomas in adults: analysis of 15 cases. Journal of experimental & clinical cancer 
research : CR 23, 201-206 
99 
 
81. Lin, Y. H., Huang, C. I., Wong, T. T., Chen, M. H., Shiau, C. Y., Wang, L. W., Ming-Tak Ho, D., 
and Yen, S. H. (2005) Treatment of spinal cord ependymomas by surgery with or without 
postoperative radiotherapy. Journal of neuro-oncology 71, 205-210 
82. Metellus, P., Figarella-Branger, D., Guyotat, J., Barrie, M., Giorgi, R., Jouvet, A., Chinot, O., 
Club de Neuro-Oncologie de la Societe Francaise de, N., and the Association des Neuro-
Oncologues d'Expression, F. (2008) Supratentorial ependymomas: prognostic factors and 
outcome analysis in a retrospective series of 46 adult patients. Cancer 113, 175-185 
83. Reni, M., Brandes, A. A., Vavassori, V., Cavallo, G., Casagrande, F., Vastola, F., Magli, A., 
Franzin, A., Basso, U., and Villa, E. (2004) A multicenter study of the prognosis and treatment of 
adult brain ependymal tumors. Cancer 100, 1221-1229 
84. Reni, M., Gatta, G., Mazza, E., and Vecht, C. (2007) Ependymoma. Critical reviews in 
oncology/hematology 63, 81-89 
85. Iunes, E. A., Stavale, J. N., de Cassia Caldas Pessoa, R., Ansai, R., Onishi, F. J., de Paiva Neto, 
M. A., de Padua Bonatelli, A., Cavalheiro, S., and Fleury Malheiros, S. M. (2011) Multifocal 
intradural extramedullary ependymoma. Case report. Journal of neurosurgery. Spine 14, 65-70 
86. Breidenbach, M., Rein, D. T., Mallmann, P., and Kurbacher, C. M. (2002) Individualized long-
term chemotherapy for recurrent ovarian cancer after failing high-dose treatment. Anti-cancer 
drugs 13, 173-176 
87. Brower, S. L., Fensterer, J. E., and Bush, J. E. (2008) The ChemoFx assay: an ex vivo 
chemosensitivity and resistance assay for predicting patient response to cancer chemotherapy. 
Methods in molecular biology 414, 57-78 
88. Kleinhans, R., Brischwein, M., Wang, P., Becker, B., Demmel, F., Schwarzenberger, T., 
Zottmann, M., Wolf, P., Niendorf, A., and Wolf, B. (2012) Sensor-based cell and tissue screening 
for personalized cancer chemotherapy. Medical & biological engineering & computing 50, 117-
126 
89. Michalova, E., Poprach, A., Nemeckova, I., Nenutil, R., Valik, D., Zaloudik, J., Vyzula, R., and 
Vojtesek, B. (2008) [Chemosensitivity prediction in tumor cells ex vivo--difficulties and 
limitations of the method]. Klinicka onkologie : casopis Ceske a Slovenske onkologicke 
spolecnosti 21, 93-97 
90. Myatt, N., Cree, I. A., Kurbacher, C. M., Foss, A. J., Hungerford, J. L., and Plowman, P. N. 
(1997) The ex vivo chemosensitivity profile of choroidal melanoma. Anti-cancer drugs 8, 756-
762 
91. Tsubouchi, H., Takao, S., and Aikou, T. (2000) Sensitivity of human pancreatic adenocarcinoma 
tumor lines to chemotherapy, radiotherapy, and hyperthermia. Human cell 13, 203-212 
92. Wichmann, G., Horn, I. S., Boehm, A., Mozet, C., Tschop, K., Dollner, R., and Dietz, A. (2009) 
Single tissue samples from head and neck squamous cell carcinomas are representative regarding 
the entire tumor's chemosensitivity to cisplatin and docetaxel. Onkologie 32, 264-272 
93. Ballard, K. S., Tedjarati, S. S., Robinson, W. R., Homesley, H. D., and Thurston, E. L. (2010) 
Embryonal rhabdomyosarcoma: adjuvant and ex vivo assay-directed chemotherapy. International 
100 
 
journal of gynecological cancer : official journal of the International Gynecological Cancer 
Society 20, 561-563 
94. Gallion, H., Christopherson, W. A., Coleman, R. L., DeMars, L., Herzog, T., Hosford, S., 
Schellhas, H., Wells, A., and Sevin, B. U. (2006) Progression-free interval in ovarian cancer and 
predictive value of an ex vivo chemoresponse assay. International journal of gynecological 
cancer : official journal of the International Gynecological Cancer Society 16, 194-201 
95. Huh, W. K., Cibull, M., Gallion, H. H., Gan, C. M., Richard, S., and Cohn, D. E. (2011) 
Consistency of in vitro chemoresponse assay results and population clinical response rates among 
women with endometrial carcinoma. International journal of gynecological cancer : official 
journal of the International Gynecological Cancer Society 21, 494-499 
96. Ness, R. B., Wisniewski, S. R., Eng, H., and Christopherson, W. (2002) Cell viability assay for 
drug testing in ovarian cancer: in vitro kill versus clinical response. Anticancer research 22, 
1145-1149 
97. Ochs, R. L., Burholt, D., and Kornblith, P. (2005) The ChemoFx assay: an ex vivo cell culture 
assay for predicting anticancer drug responses. Methods in molecular medicine 110, 155-172 
98. Peters, D., Freund, J., and Ochs, R. L. (2005) Genome-wide transcriptional analysis of 
carboplatin response in chemosensitive and chemoresistant ovarian cancer cells. Molecular 
cancer therapeutics 4, 1605-1616 
99. Mi, L., Hood, B. L., Stewart, N. A., Xiao, Z., Govind, S., Wang, X., Conrads, T. P., Veenstra, T. 
D., and Chung, F. L. (2011) Identification of potential protein targets of isothiocyanates by 
proteomics. Chemical research in toxicology 24, 1735-1743 
100. Zhang, Y. (2001) Molecular mechanism of rapid cellular accumulation of anticarcinogenic 
isothiocyanates. Carcinogenesis 22, 425-431 
101. Kelloff, G. J., Crowell, J. A., Steele, V. E., Lubet, R. A., Boone, C. W., Malone, W. A., Hawk, E. 
T., Lieberman, R., Lawrence, J. A., Kopelovich, L., Ali, I., Viner, J. L., and Sigman, C. C. (1999) 
Progress in cancer chemoprevention. Annals of the New York Academy of Sciences 889, 1-13 
102. Lamy, E., Scholtes, C., Herz, C., and Mersch-Sundermann, V. (2011) Pharmacokinetics and 
pharmacodynamics of isothiocyanates. Drug metabolism reviews 43, 387-407 
103. Niranjan, A., Kano, H., Iyer, A., Kondziolka, D., Flickinger, J. C., and Lunsford, L. D. (2015) 
Role of adjuvant or salvage radiosurgery in the management of unresected residual or progressive 
glioblastoma multiforme in the pre-bevacizumab era. Journal of neurosurgery 122, 757-765 
104. Sims, J. S., Ung, T. H., Neira, J. A., Canoll, P., and Bruce, J. N. (2015) Biomarkers for glioma 
immunotherapy: the next generation. Journal of neuro-oncology  
105. Gil-Gil, M. J., Mesia, C., Rey, M., and Bruna, J. (2013) Bevacizumab for the treatment of 
glioblastoma. Clinical Medicine Insights. Oncology 7, 123-135 
106. Caroli, M., Locatelli, M., Campanella, R., Motta, F., Mora, A., Prada, F., Borsa, S., Martinelli-
Boneschi, F., Saladino, A., and Gaini, S. M. (2007) Temozolomide in glioblastoma: results of 
101 
 
administration at first relapse and in newly diagnosed cases. Is still proposable an alternative 
schedule to concomitant protocol? Journal of neuro-oncology 84, 71-77 
107. Kim, H. R., Kim, K. H., Kong, D. S., Seol, H. J., Nam, D. H., Lim do, H., and Lee, J. I. (2015) 
Outcome of salvage treatment for recurrent glioblastoma. Journal of clinical neuroscience : 
official journal of the Neurosurgical Society of Australasia 22, 468-473 
108. Combs, S. E., Rieken, S., Wick, W., Abdollahi, A., von Deimling, A., Debus, J., and Hartmann, 
C. (2011) Prognostic significance of IDH-1 and MGMT in patients with glioblastoma: one step 
forward, and one step back? Radiation oncology 6, 115 
109. Labussiere, M., Sanson, M., Idbaih, A., and Delattre, J. Y. (2010) IDH1 gene mutations: a new 















Sarah Elizabeth Daron-Mathis 
 
1141 10th Ave, Huntington, WV 25701 




PhD Graduate student and researcher, Biomedical Sciences, School of Medicine, Marshall 
University, Huntington, WV        2009-Present 
 
Education 
PhD Biomedical Sciences, Marshall University, Huntington, WV May 2015 
MS Biological Sciences, Marshall University, Huntington, WV May 2009  
BS Biological Sciences, Marshall University, Huntington, WV July 2007 
 
Teaching Experience 
Adjunct Professor, Microbiology GE 257, ITT Tech, 2014   
Lab Instructor, Cell Biology BSC 322, Marshall University, 2009 
Lab Instructor, Cell Biology BSC 322, Marshall University, 2008 
Substitute Lecturer, Human Biology BSC 105, Marshall University, 2008 
Lab Instructor, Principles of Biology, Clearwater Christian College, 2003 
 
Research Laboratory Experience 
Research Assistant, Biochemistry and Microbiology Department, Marshall University (2009-
present) 
International Exchange Graduate Research, Council for National Research (CNR) Rome, Italy 
(Spring 2009) 
Research Assistant, Biology Department, Marshall University (2006-2009) 
 
 
Qualification Summary & Skill Set 
Biomedical Lab Manager with expertise in microbiology techniques, including aseptic technique, 
cell culture, autoclaving and media preparation. Experienced in tissue engineering and chemo-
sensitivity assays. 
 
• Expert in Cell Culture of established and Primary Cell lines 
• Experienced in tissue engineering 
• Expert in Microgravity engineering 
• Proficient in analytical techniques  
• Expert in Flow Cytometry  
• Skilled in viability assays 
• Expert in Microscopy 
• Operations management 
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• Staff supervision and training 
• Complex problem solving 
• Quality control 




Graduate Research Fellowship Program - NASA West Virginia Space Grant Consortium (June 
2008) 
Charles C. Gould Scholarship- Marshall University (May 2008)   
Travel Grant - American Society for Gravitational and Space Biology (October 2007) 
Travel Grant - NASA West Virginia Space Grant Consortium (September 2007) 
Graduate Research Fellowship Program - NASA West Virginia Space Grant Consortium (May 
2007) 
NASA Space Grant Scholarship – NASA (November 2006) 
College of Science Tuition Waiver Scholarship Award - Marshall University (November 2006) 
 
Posters 
Undergraduate Research Day at the Capitol     February 8th 2007 
 Presentation was given at West Virginia’s state capital to the states delegates about the 
current research project on “Bioreactor Production of Plant Pharmaceuticals.”  
 
Sigma Xi         April 28th 2007 
Presentation was given at Marshall University to fellow students and faculty about the 
current research project on “Medicinal Plant Cell Cultures in Microgravity-based Bioreactor.”  
 
STaR Symposium       September 17th 2007 
Presentation was given at Waterfront Place Hotel in Morgantown, WV to fellow students 
and faculty in the state of West Virginia about the current research project on “Production of 
Bioproducts in a Microgravity-based Bioreactor.” 
 
American Society for Gravitational Space Biology 23rd Annual Meeting  
October 25-28th 2007 
Presentation was given at AMES Research Center to fellow students and faculty from 
around the world about the current research project on “Selection of Tumor Stem Cells from 
Tumor Cell lines.”  
  
Life in Space for Life on Earth     June 22-27th 2008 
 This presentation was given at a conference in Angers, France. This conference was 
hosted by European Space Agency (ESA) along with International Society for Gravitational 
Physiology (ISGP), American Society for Gravitational Space Biology (ASGSB), and European 
Low Gravity Research Association (ELGRA). Presentation was given about “Rapid Selection 
and Proliferation of Cancer Stem Cells in a NASA Developed Microgravity Bioreactor.” 
 
Advances in Cell Differentiation and Development Symposium November 14th, 2008 
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Cell Differentiation and Development Center (CDDC) First Annual Symposium was held 
at Memorial Student Center, Marshall University where a Presentation was given to fellow 
students and faculty from the region on the “Selection of Tumor Stem Cells from Tumor Cell 
lines.” This was a competitive poster competition where I received first place.  
 
STaR Symposium       April 13-14th, 2009 
 Presentation was given at Charleston Marriott Town Center in Charleston, WV to fellow 
students and faculty in the state of West Virginia about the current research project on “Rapid 
Selection and Proliferation of Cancer Stem Cells in a NASA Developed Microgravity 
Bioreactor: Chemotherapeutic Implications.” 
 
AICR Research Conference      November 4-6th, 2009 
AICR Research Conference held its 20th Annual Conference in Washington, D.C. at the 
Hilton. Presentations were given to fellow students and faculty from the region on “Omega-3 and 
-6 fatty acids select proliferate and sensitize colorectal cancer stem-like cells to chemotherapy.” 
 
Marshall University Research Day     March 20th, 2012 
 This presentation was given orally at Marshall University Joan C. Edwards School of 
Medicine hosts 24th annual Research Day was held at Cabell Huntington Hospital in Huntington, 
WV to fellow students and faculty on “Personalized Chemotherapy Identified for a Case of 
Progressing Spinal Ependymoma.” 
 
 
Advances in Cell Differentiation and Development Symposium March 23rd, 2012 
Cell Differentiation and Development Center (CDDC) Second Annual Symposium was 
held at Memorial Student Center, Marshall University where a Presentation was given to fellow 
students and faculty from the region on the “Personalized Chemotherapy Identified for a Case of 
Progressing Spinal Ependymoma.” This was a competitive poster competition where I received 
first place in the graduate student category.  
 
STaR Symposium       April 20-21st, 2012 
 Presentation was given at West Virginia State University in Institute, WV to fellow 
students and faculty in the state of West Virginia about the current research project on 
“Personalized Chemotherapy Identified for a Case of Progressing Spinal Ependymoma.” 
 
Center for Clinical and Translational Science Spring Conference (CCTS)        March 29th 2012.  
Presentation was given in Lexington Kentucky to fellow students and faculty of the 
region about the current research project on “Personalized Chemotherapy Identified for a Case of 
Progressing Spinal Ependymoma.” 
 
Appalachian Regional Cell Conference (ARCC)     October 12th 2012.  
 Presentation was given at the Charleston Area Medical Center in Charleston, WV to 
fellow students and faculty of the region about the current research project on “Personalized 
Chemotherapy Identified for a Case of Progressing Spinal Ependymoma.” 
 
Marshall University Research Day     March 11th-12th, 2013 
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 This presentation was given orally at Marshall University Joan C. Edwards School of 
Medicine hosts 25th annual Research Day was held at Cabell Huntington Hospital in Huntington, 
WV to fellow students and faculty on “Resveratrol suppresses lipogenesis, growth and viability 
of pancreatic and breast cancer stem-like cells.” 
 
Appalachian Regional Cell Conference (ARCC)     October 26th 2013.  
 Oral presentation was given at the Charleston Area Medical Center in Charleston, WV to 
fellow students and faculty of the region about the current research project on “ChemoID® a 





Chemo-Predictive Assay for Targeting Cancer Stem-Like Cells in Patients Affected by Brain 
Tumors. Sarah E. Mathis, Anthony Alberico, Rounak Nande, Walter Neto, Logan Lawrence, 
Danielle R. McCallister, James Denvir, Gerrit A. Kimmey, Mark Mogul, Gerard Oakley, Krista 
L. Denning, Thomas Dougherty, Jagan V. Valluri, Pier Paolo Claudio. PLoS ONE, 2014 Aug 21; 
9(8): e105710. 
 
Rapid Selection and Proliferation of CD133 (+) Cells from Cancer Cell Lines: Chemotherapeutic 
Implications. Sarah E. Kelly, Altomare Di Benedetto, Adelaide Greco, Candace M. Howard, 
Vincent E. Sollars, Donald A. Primerano, Jagan V. Valluri, Pier Paolo Claudio.  PLoS ONE, 
2010 Apr 8;5(4):e10035 
 
Eradication of therapy-resistant human prostate tumors using an ultrasound-guided site-specific 
cancer terminator virus delivery approach.  Greco A, Di Benedetto A, Howard CM, Kelly S, 
Nande R, Dementieva Y, Miranda M, Brunetti A, Salvatore M, Claudio L, Sarkar D, Dent P, 
Curiel DT, Fisher PB, Claudio PP. Mol Ther. 2010 Feb;18(2):295-306.  
 
Protein Expression in Glycine max Cells under Microgravity Conditions. Jagan Valluri, W. 
Kelly, and S. Kelly October 2008 Gravitational and Space Biology 
 
 
Honor and Awards 
First Place poster competition for graduates and post docs –Advances  March 2012 
in Cell Differentiation and Development Symposium  
Best in Group poster competition - ARCC Applachain Regional Cell October 2012 
Conference  
First Place poster competition for graduates and post docs    November 2008 
-Advances in Cell Differentiation and Development Symposium      
Graduate Research Fellowship Program      June 2008 
 - NASA West Virginia Space Grant Consortium      
Charles C. Gould Scholarship- Marshall University     May 2008 
Travel Grant - American Society for Gravitational and Space Biology October 2007 
Travel Grant - NASA West Virginia Space Grant Consortium  September 2007 
Graduate Research Fellowship Program      May 2007 
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 - NASA West Virginia Space Grant Consortium        
NASA Space Grant Scholarship - NASA     November 2006 
College of Science Tuition Waiver Scholarship Award   November 2006 
- Marshall University  
Dean's List - Marshall University      May 2006  
National Dean's List - The National Dean's List    May 2006 
Dean's List - Marshall University      December 2005 
Dean's List - University of Cincinnati     December 2003 




National Association of Professional Women (NAPW) 2012-Present, Member 
International Bujinkan Dojo Association (IBDA) 2011-Present, Member 
Bujinkan Student Organization 2011-Present, Secretary (2011-2012) President (2012-2013) 
Southside Elementary Parent Teacher Organization (PTO) 2010-Present, Member 
American Society for Gravitational Space Biology (ASGSB) 2007-2008, Student Member  




Cabell Huntington Hospital, Physical Therapy Department May 2006- August 2006 
WV EPsCOR Both worker at state fair August 2007 
Teaching Substitute for Biology 105 Dr. Valluri April 2008 
Visiting Research at CNR in Rome, Italy Spring 2009 
Team Mom for DC Express peewee football 2010 season 
Game Night Organizer for Ona Children’s Home March 2011 
Guest Lecturer for Biology 105 at ITT tech August 5th 2011 
